JPS61500915A - New aryl acetic acid derivatives - Google Patents
New aryl acetic acid derivativesInfo
- Publication number
- JPS61500915A JPS61500915A JP60500499A JP50049985A JPS61500915A JP S61500915 A JPS61500915 A JP S61500915A JP 60500499 A JP60500499 A JP 60500499A JP 50049985 A JP50049985 A JP 50049985A JP S61500915 A JPS61500915 A JP S61500915A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- acid
- hydroxy
- water
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 aryl acetic acid derivatives Chemical class 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 93
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 150000002596 lactones Chemical class 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000006361 alkylene amino carbonyl group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 79
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 238000000921 elemental analysis Methods 0.000 description 42
- 230000008018 melting Effects 0.000 description 42
- 238000002844 melting Methods 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 22
- 235000011121 sodium hydroxide Nutrition 0.000 description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- 238000010183 spectrum analysis Methods 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 13
- 239000005457 ice water Substances 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 description 9
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229960003424 phenylacetic acid Drugs 0.000 description 7
- 239000000052 vinegar Substances 0.000 description 7
- 235000021419 vinegar Nutrition 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 229960003742 phenol Drugs 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 241000219112 Cucumis Species 0.000 description 4
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- UWQIEDGNGUIPKS-UHFFFAOYSA-N benzene 2,2,4-trimethylpentane Chemical compound C1=CC=CC=C1.CC(C)CC(C)(C)C UWQIEDGNGUIPKS-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- BNQRSYFOIRGRKV-UHFFFAOYSA-N methyl 2-(2-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1OC BNQRSYFOIRGRKV-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CCVYRRGZDBSHFU-UHFFFAOYSA-N (2-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1O CCVYRRGZDBSHFU-UHFFFAOYSA-N 0.000 description 2
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BVBSGGBDFJUSIH-UHFFFAOYSA-N Methyl (2-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1O BVBSGGBDFJUSIH-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000750631 Takifugu chinensis Species 0.000 description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
- 244000250129 Trigonella foenum graecum Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- OHPLLNOHNYTVPU-UHFFFAOYSA-N acetic acid;2-methylphenol Chemical compound CC(O)=O.CC1=CC=CC=C1O OHPLLNOHNYTVPU-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPUJEWVVTKLMQI-UHFFFAOYSA-N benzene;ethoxyethane Chemical compound CCOCC.C1=CC=CC=C1 WPUJEWVVTKLMQI-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- HPJMSFQWRMTUHT-UHFFFAOYSA-N (4-hydroxyphenyl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(O)C=C1 HPJMSFQWRMTUHT-UHFFFAOYSA-N 0.000 description 1
- SWFHGTMLYIBPPA-UHFFFAOYSA-N (4-methoxyphenyl)-phenylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 SWFHGTMLYIBPPA-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SFPLEZVLRMSLCX-UHFFFAOYSA-N 1-chloro-2-methoxy-3-methylbenzene Chemical class COC1=C(C)C=CC=C1Cl SFPLEZVLRMSLCX-UHFFFAOYSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- IUJAAIZKRJJZGQ-UHFFFAOYSA-N 2-(2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Cl IUJAAIZKRJJZGQ-UHFFFAOYSA-N 0.000 description 1
- FUQIESFELQQVCA-UHFFFAOYSA-N 2-(2-hydroxy-3-methyl-5-propanoylphenyl)acetic acid Chemical compound CCC(=O)C1=CC(C)=C(O)C(CC(O)=O)=C1 FUQIESFELQQVCA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZLRAITVSGOWJEZ-UHFFFAOYSA-N 2-[3-(2-phenylethynyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C#CC=2C=CC=CC=2)=C1 ZLRAITVSGOWJEZ-UHFFFAOYSA-N 0.000 description 1
- JLWMMYZWEHHTFF-UHFFFAOYSA-N 2-[6-(3-carbamimidoylphenoxy)-4-[di(propan-2-yl)amino]-3,5-difluoropyridin-2-yl]oxy-5-(2-methylpropylcarbamoyl)benzoic acid Chemical compound OC(=O)C1=CC(C(=O)NCC(C)C)=CC=C1OC1=NC(OC=2C=C(C=CC=2)C(N)=N)=C(F)C(N(C(C)C)C(C)C)=C1F JLWMMYZWEHHTFF-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GYLKKXHEIIFTJH-UHFFFAOYSA-N 3-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC(C#N)=C1 GYLKKXHEIIFTJH-UHFFFAOYSA-N 0.000 description 1
- NPFYZDNDJHZQKY-UHFFFAOYSA-N 4-Hydroxybenzophenone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 NPFYZDNDJHZQKY-UHFFFAOYSA-N 0.000 description 1
- QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 1
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NXXKVSOAXHRYBP-UHFFFAOYSA-N C1=CC(=CC=C1C(=O)C2=CC(=C(C=C2)O)C(=O)O)[N+](=O)[O-] Chemical compound C1=CC(=CC=C1C(=O)C2=CC(=C(C=C2)O)C(=O)O)[N+](=O)[O-] NXXKVSOAXHRYBP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101150017965 PGD1 gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CHZVHNZRFPALHO-UHFFFAOYSA-N [Br].[Na] Chemical compound [Br].[Na] CHZVHNZRFPALHO-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- VXHQWKIKXQTTEW-UHFFFAOYSA-N acetic acid;anisole Chemical compound CC(O)=O.COC1=CC=CC=C1 VXHQWKIKXQTTEW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- CIMMACURCPXICP-PNQRDDRVSA-N prostaglandin D1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)[C@@H](O)CC1=O CIMMACURCPXICP-PNQRDDRVSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- BXBUVIPNRGDTNE-UHFFFAOYSA-N sodium;hydrobromide Chemical compound [Na].Br BXBUVIPNRGDTNE-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 新規アリール酢酸誘導体 本発明は、ヤ在的に15−ヒドロキシ−プロスタブランジンデヒドロゲナーゼ( PGDH)に対する阻害効果を有する新規化合物に関するものでおる。本発明は 又、該新規化合物の製造及びこれらを含む医薬組成物に関するものである。[Detailed description of the invention] New arylacetic acid derivatives The present invention specifically relates to 15-hydroxy-prostabrandin dehydrogenase ( The present invention relates to a novel compound that has an inhibitory effect on PGDH. The present invention It also relates to the production of the novel compounds and pharmaceutical compositions containing them.
PGD)1阻沓剤の医薬としての有用性に関する将来の可能性については未だ充 分に臨丘さnて来てはいない。しかしながら、生体中に於いてグロスタグランジ ンが非常に重要な役割を担っていることは周知でちゃ、これ故にプロスタグラン ジンの仕成ろるいは分解のいずれかを干渉するような4%@はどれも医療上のX 要な手段になシ得る可能性がある。プロスタグランジンの持つ所鯖細胞保護効果 (cytoprotective effect)は潰瘍治療の分野に於いては 比較的良く央られていることであるatかしそれにもかかわらず、治療過程に於 いてプロスタグランジンの投与はこれまで一度も大規模に利用され之ことはなか った。なぜならば、投与されたブロスタグ2ンジンはin vivo に於いて は極めて短い時間しか存在できないからである。プロスタグランジンを投与する ことエフも、内因性グロスタグランジンの分解を阻害する薬物の方がおそらくも つと非常に成功するものがも知れない。The future potential of PGD1 inhibitors as pharmaceuticals remains unclear. Linqiu hasn't come yet. However, in living organisms, gross tag grunge It is well known that prostagland plays a very important role. Any 4% @ that interferes with either the production process or decomposition of gin is a medical X. There is a possibility that it can be obtained by any necessary means. The protective effect of prostaglandins on mackerel cells (cytoprotective effect) in the field of ulcer treatment. Although it is relatively well-regulated, there are still However, the administration of prostaglandins has never been used on a large scale. It was. This is because the administered Brostag 2 in vivo This is because it can only exist for a very short time. Administer prostaglandins Also, drugs that inhibit the breakdown of endogenous grosstaglandin are probably more effective. I don't know if there are any that are very successful.
内因性グロスタグ2ンジン(endogenous prostaglandi ns ) #i炎炎症過圧於いても主要な役割を担っている。リューマチ様関節 炎(rheurr+atoid arthritis )の治療に於いてプロス タグランジン@成の阻害剤を用いることは現在の常套手段である。しかし今頃で は、この手段は単なる対症療法にすぎないと考えられてお9、笑際のところある 極のグロスタグランジンは今でも非常に有効である可能性がるると信じられてい る。この意味においても同様に、PGDHによるグロスタグランジンの分解を阻 害することは大変価値のあるものである可能性がある。更に本発明による新規化 合v3を応用できる重要な医学分野になる可能性があるものとしては、プロスタ グランジンが所望の調節因子(controlling factors )と してwiすることのできる全ての分野、即ち循撫系の病気、ガン、妊娠、細胞副 産などの分野がある。endogenous prostaglandi ns) #i Inflammation It also plays a major role in inflammatory overpressure. rheumatoid joints Pros in the treatment of inflammation (rheurr + atoid arthritis) It is current practice to use inhibitors of taglandin formation. But by now However, this method is considered to be merely a symptomatic treatment9, and it is on the verge of laughter. It is believed that polar Glostaglandin may still be very effective. Ru. In this sense, the decomposition of grosstaglandin by PGDH is also inhibited. Harm can be very valuable. Furthermore, novelty according to the present invention Prosthetic surgery is a potentially important medical field in which Synv3 can be applied. Grandins interact with the desired controlling factors. All areas that can be treated include circulatory system diseases, cancer, pregnancy, and cellular disorders. There are fields such as industrial production.
PGDHに対する阻害効果を持つ化合物として公知のものの例としては欧州特許 公開第21229号明細書に記載されているようなアゾ化合物が挙げられる。Examples of compounds known to have an inhibitory effect on PGDH include European patents. Examples include azo compounds as described in Japanese Publication No. 21229.
以前から用いられているこれらのアゾ化合物には数多くの著しく重大な欠点がお る為に、芙除の実用医薬としてのこれら化合物の有用性が減じられてい友。非常 に重大な欠点というのは、動物及びヒトはそのアゾ化合物を代謝作用にニジ還元 的に開裂してしまい、その結果2つの芳香族アミンが生じてし1うという事笑で ある。この型の物質代謝は特に(1)肝澹及びtii)入励円で多食に生起し、 大腸に於いて(グ腸内微小碩吻(inteslnalmicroflora ) 即ち、通常腸内に生息している細菌により作られる強い還元条件の友めにこの物 質代謝が促進される。These previously used azo compounds have a number of significant drawbacks. The usefulness of these compounds as practical medicines has been diminished due to the fact that emergency A significant drawback is that animals and humans are unable to reduce the metabolic effects of azo compounds. The result is that two aromatic amines are produced. be. This type of metabolism occurs especially in (1) hepatic and tii) hyperphagia, In the large intestine (intestinal microflora) That is, this substance is a friend of the strong reducing conditions created by bacteria that normally live in the intestines. Quality metabolism is promoted.
このような物質代謝によって、投与された童のかな)の地方が消失させられる傾 向[6る。すでにこのこと自体不利な点である。しかしながら最も重大な問題は 前記の芳香族アミン、例 ゛えばアニリン、クロロアニリン等の存在に起因する ものである。Due to this kind of substance metabolism, the area of the children to whom it was administered tends to disappear. Direction [6ru. This is already a disadvantage in itself. However, the most important problem is Due to the presence of the above-mentioned aromatic amines, such as aniline, chloroaniline, etc. It is something.
1nViVQ でこれらのアミンが形成されることを考えるならば、該アゾ化合 物を爽際の医療に於いて用いることは一役的には不可能である。非常に4殊な場 合にだけ、in vivo で形成さnたアミンが、該アゾ化合物を笑際の治療 に用いることを許すだけの充分低い毒性しか持っていないものと考えられる。こ の欠点よシも程度は低いが無視できない欠点としてこれらアゾ化合物の持つ強い 着色作用(coloring )があり、最もひどい場合には、患者の皮膚、眼 などの色を明らかKR別できる程に変えてしまうという好ましくないものである 。Considering that these amines are formed with 1nViVQ, the azo compound It is not possible to use this product in front-line medical care. very special place Only when the amines formed in vivo make the azo compound active in the treatment It is thought that the toxicity is low enough to permit its use in child The disadvantages of these azo compounds, although to a lesser extent, cannot be ignored. It has a coloring effect, and in the most severe cases it can cause damage to the patient's skin and eyes. This is undesirable as it changes the colors such as KR to such an extent that it is clearly distinguishable from KR. .
改良され7zPGDH阻害剤及びその製造方法t−提供することが本発明の目的 でちる。更に、本発明の目的は改良され九医東組成の及び該阻害剤を含む治療方 f、を提供することでらる。OBJECT OF THE INVENTION It is an object of the present invention to provide an improved 7zPGDH inhibitor and a method for producing the same. Dechiru. Furthermore, it is an object of the present invention to provide improved therapeutic methods containing the composition and inhibitors thereof. By providing f.
新規化合物は以下の講這式: 〔式中、&及び鳥は水素原子又は低級アルキルで、好ましくは烏は水素原子を示 し: 鳥は水素原子、低級アルキル又は任意に置換されるフェニルを示し; 〜烏及び鳥は水素原子、ハロゲン、低級アルキル、低級アルコキシ、シアノ、カ ルボキシ又はニトロを示し、R4から鳥の基のうちの少なくとも1つは水素原子 であシ;&から鳥、までは水素原子、ハロゲン、シアノ、低級アルキル、トリフ ルオロメチル、低級アルコキシ、ヒドロキシ、低級アシル、低級アルコキシカル ボニル、N、N−ジ低級アルキル−アミノカルボニル又FiN、N−低級アルキ レンーアミノカルボニルを示し、鳥から鳥。は更にカルボキシでもあや得、烏か ら鳥1のうちの少なくとも2つは常に水素原子であり、好ましくは&及び飄、は 水素原子、ハロゲン、シアン、低級フルキル、トリフルオロメチル、低級アルコ キシ、ヒドロキシ又は低級アシルであシ: 一人−は−co+、−CH意−CO−、−0H=C)i−、−C)i=cH−C 〇−又は前記中の水素原子が低級アルキル基と置換さ1′シた対応する基を示し ;もしカルボニル基が存在する時はそn(は式[11のリングI’LK結曾して いること)〕をもつ化什物であるフ 不明細書中及び請求のQ白に於いて、”低級アルキル”。The new compound has the following formula: [In the formula, & and Tori represent a hydrogen atom or lower alkyl, and preferably Crow represents a hydrogen atom.] death: Bird represents a hydrogen atom, lower alkyl or optionally substituted phenyl; ~ Crows and birds contain hydrogen atoms, halogens, lower alkyl, lower alkoxy, cyano, and carbon. represents ruboxy or nitro, and at least one of the avian groups from R4 is a hydrogen atom From & to bird, hydrogen atom, halogen, cyano, lower alkyl, triph. fluoromethyl, lower alkoxy, hydroxy, lower acyl, lower alkoxyl Bonyl, N, N-di-lower alkyl-aminocarbonyl or FiN, N-lower alkyl Indicates ren-aminocarbonyl, bird to bird. Is it even more difficult to use carboxy? At least two of the atoms 1 are always hydrogen atoms, preferably & and 鰄. Hydrogen atom, halogen, cyanide, lower fulkyl, trifluoromethyl, lower alkyl Oxy, hydroxy or lower acyl: One person - is -co+, -CH -CO-, -0H=C)i-, -C)i=cH-C 〇- or the corresponding group in which the hydrogen atom in the above is substituted with a lower alkyl group ; If a carbonyl group is present, then the ring I'LK of formula [11] Fu is a monster with "Lower alkyl" in the unknown specification and in the Q white of the claim.
1低級アシル”及び゛低級アルコキシ”という用語は好ましくは6よシ少ない炭 素原子を含む基を示している。The terms ``lower acyl'' and ``lower alkoxy'' preferably contain less than 6 carbons. Indicates a group containing an elementary atom.
本発明は更KR,が水素原子であるラクトンもま几含み、少なくとも1つ〔レカ ルiキシ基を含む化合物の塩をも含む。好適な塩は医薬上許容され得、治又上活 性があるものである。The present invention also includes lactones in which KR is a hydrogen atom, and at least one It also includes salts of compounds containing a hydroxy group. Suitable salts are pharmaceutically acceptable and therapeutically active. It has a certain nature.
適当な塩としてはナトリウム、カリウム及びカルシウムのような金属塩、又は例 えばジェタノールアミン、トリエI’/−#アミン、N−メチル−グルカミン; トリス−ヒドロキシメチル−メチルアミン等のような有機アミンとの塩である。Suitable salts include metal salts such as sodium, potassium and calcium, or e.g. For example jetanolamine, Trie I'/-#amine, N-methyl-glucamine; Salts with organic amines such as tris-hydroxymethyl-methylamine and the like.
本発明の新規化合物はほとんど完全に@色であシ、アゾ化合物の場合と似たよう なT9.得で物質代謝されることはない。従って、式(11の化合物はアゾ化せ 吻固肩のチくの欠点がない。こり化合物のPGDH阻讐効果はアゾ化合物シて叙 べ同等ないしそれ以上でらるつ 不発明の化合物の主要な利点としては、胃腸管から吸収される能力という点に於 いて著しくそれらの間で違いがあるような基をこの化合物が含んでいるというこ とが挙げろnる。The new compounds of the present invention are almost completely colored, similar to that of azo compounds. T9. It is not metabolized by the body. Therefore, the compound of formula (11) cannot be azotized. There is no drawback of a stiff nose and shoulders. The PGDH inhibitory effect of stiffness compounds has been demonstrated by azo compounds. It's the same or better than that. A major advantage of the uninvented compound is its ability to be absorbed from the gastrointestinal tract. This means that the compound contains groups that differ significantly between them. I'll list it.
りまシ本発明は、血流中に急速に且つ完全に吸収されてしまうという全身的な効 果を得る丸めの優れた特性をもつ化合物を含んでいる。一方、他の化合物は吸収 されにくく従って胃腸管に電線されることになシ、つまシ式(1)のある種の化 合物は、例えば背潰擾、限局性回腸炎(クローン病)及び潰瘍性大腸炎などの胃 腸管の病気に対する局所活a能力を備え得るということを意味するものである。The present invention has systemic effects that are rapidly and completely absorbed into the bloodstream. Contains compounds with excellent rounding properties. On the other hand, other compounds are absorbed Some forms of the Tsumashi method (1) are less susceptible to being wired into the gastrointestinal tract. The compound can be used to treat gastric conditions such as back ulcers, localized ileitis (Crohn's disease), and ulcerative colitis. This means that it can have the ability to locally act on diseases of the intestinal tract.
本発明の化合物はそれ自体公知である方法の様々な組合せによって製造され得る 。一般的に概観すると、これらの方法は6つの異なる一般タイブ&て分類され得 る。笑際の製造に於いて選択されるある%足の方法はしはしは2つ以上りこのよ うな一般タイブの方法の組み合せである。The compounds of the invention may be prepared by various combinations of methods known per se. . In general overview, these methods can be categorized into six different general types. Ru. There are a certain number of methods selected in the manufacture of wafers, such as two or more rigs. It is a combination of common types of methods.
一般タイブ囚 第1の一般タイブ人は以下の式 〔式中、XI−jOHによって置換され得る基を示し、鳥から鳥。General type prisoner The first general type person is the following formula [In the formula, indicates a group that can be substituted by XI-jOH, from bird to bird.
及び人は式11>中と同じ意味を有するl〕の化合物を処理してXを0HKtl t換する。X基の例としてはアミノ、ニトロ、低級アルコキシ、アリルオキシ、 低級アシルオキシ、アリールオキシ、低級アルキルスルホニルオキシ又はアリー ルスルホニルオキシがちる。Xが低級アルコキシの場合ニは、反応は強酸試薬例 えば硫酸9項は又は臭化水素酸のような強鉱酸によって任意に水の存在下に於い て処理することで行なわれる。強酸を用いる代シK、塩化アルミニウム、三臭化 ホウ素のようなルイス酸の存在下で反応させても良い。and one can treat the compound of formula 11>l with the same meaning as in formula 11 to convert X to 0HKtl t exchange. Examples of the X group are amino, nitro, lower alkoxy, allyloxy, Lower acyloxy, aryloxy, lower alkylsulfonyloxy or aryl Rusulfonyloxy is present. When X is lower alkoxy, the reaction is performed using a strong acid reagent example. For example, sulfuric acid (9) can be prepared by a strong mineral acid such as hydrobromic acid, optionally in the presence of water. This is done by processing the K, aluminum chloride, tribromide using strong acids The reaction may be carried out in the presence of a Lewis acid such as boron.
x6=7リルオキシの場合には、Xがアルコキシである場合と同じ方法で反応さ せるか、又は好ましくは酸性媒体中の水の存在下で二重え合を異性化して対応す るプロペニル銹導体を形成させこれを該酸性媒体中で急速に加水分解させる方法 によって反応させる この異性化反応は例えばパラジウム又はプラチナの様な金 属触媒と処理することVこよって連取できる。Xが低級アシルオキシ、アリール オキシ、低級アルキルスルホニルオキシ又はアリールスルホニルオキシの場合に は、0I−IK二Si供反応は、好ましくは水中又は水と混合し水を含む活媒甲 でのアルカリ性加水分解によって行なわれる。反応終了後、得られる反応混合物 を中和する。When x6=7lyloxy, the reaction is done in the same way as when X is alkoxy. or by isomerizing the double polymer, preferably in the presence of water in an acidic medium. A method of forming a propenyl rust conductor and rapidly hydrolyzing it in the acidic medium. This isomerization reaction is performed using gold such as palladium or platinum. By treating with a catalytic converter, continuous recovery can be achieved. X is lower acyloxy, aryl In the case of oxy, lower alkylsulfonyloxy or arylsulfonyloxy The 0I-IK diSi donor reaction is preferably carried out in water or in an active medium containing water mixed with water. It is carried out by alkaline hydrolysis at . After the reaction is complete, the resulting reaction mixture neutralize.
XがNH,の場合には、ジアゾ化し次いでこのジアゾニウム塩を通常の加水分解 することによって反応が最も好適九行なわれる。When X is NH, the diazonium salt is diazotized and then subjected to conventional hydrolysis. The reaction is most preferably carried out by doing this.
XがNO,の場合には、まず最初にNOx基をアミ゛ノに還元し次いで上述のよ うにアミノ基を0)IK[換する。When X is NO, the NOx group is first reduced to amino and then the above-mentioned The amino group of sea urchin is converted to 0)IK[.
一般タイブB 第2の一般タイブは以下の式 %式% 〔式中、Yは−C馬R3000Bqで置換され得る基を示し、烏から馬1及び人 は式(1)中と43じ意味を有するI〕の化合物を処理してYを一〇R,R,− 000R,rに置換する。General type B The second general type is the following formula %formula% [In the formula, Y represents a group that can be substituted with -C Uma R3000Bq, and from Karasu to Uma 1 and Human is treated with the compound I] having the same meaning as in formula (1) to convert Y to 10R,R,- Replace with 000R,r.
YC1f!lトしテ#iH、−O暉R5−CN、 CRaR5CH=CH* 。YC1f! #iH, -0R5-CN, CRaR5CH=CH*.
−Co−COO1’L (Rは低級アルキル)、−0(sa)鳥−COO馬t( R及び鳥!は水素又は低級アルキル) 、 −c(oR)2−c目×、−によ( Rは低級アルキル及びX、はヨウ素、アルキルスルホニルオキシ又はアリールス ルホニル、オキシ)が、チる。-Co-COO1'L (R is lower alkyl), -0(sa) bird-COO horse t( R and bird! is hydrogen or lower alkyl), -c(oR)2-cth x, -by( R is lower alkyl and X is iodine, alkylsulfonyloxy or aryls Ruphonyl, oxy) causes a chill.
YがH(0191合、反応FI Xz Cr1dLz−COORI (XsはO H又はハロゲンでらシ得る)を用いたアップキル化によって行なわする。もし為 がハロゲンの場合には該反応をアルカリ性条件下で行ない0−アルキル化午成物 に対するC−アルキル化生成物の収率を最高にす6のが艮い。好適には該反応は 無水条件下でん:Ct、 。Y is H (0191, reaction FI Xz Cr1dLz-COORI (Xs is O This is accomplished by upkylation using H or halogens. What if? When is a halogen, the reaction is carried out under alkaline conditions to form an 0-alkylated product. 6 to maximize the yield of the C-alkylated product. Preferably the reaction is Under anhydrous conditions: Ct.
5nO44又はTiat、などのルイス酸の存在下で行なわれる。X、が0H( 7)場合ICrX、(a>R,及び−の両刀とも低級アルキル又はtb)鳥が任 意にRaされたフェニルで鳥が水素原子又は低級アルキルのうちのどちら力)− 万であることが必要で66゜為がOHである場合の反応は好ましくは例えば硫酸 のような鉱νの存在下で行なわれる。It is carried out in the presence of a Lewis acid such as 5nO44 or Tiat. X, is 0H ( 7) If ICrX, (a>R, and - are both lower alkyl or tb) In the phenyl with Ra, which one is hydrogen atom or lower alkyl) - When the reaction temperature is 66° and OH is required, the reaction is preferably carried out using, for example, sulfuric acid. It is carried out in the presence of minerals such as ν.
Yが−C馬R,−ONである場合は、反応はそれ自体公知の方法によって、アル カリ性又はば性加水分解によって行なわれる。When Y is -C R, -ON, the reaction is carried out by methods known per se, It is carried out by caustic or caustic hydrolysis.
XがC−〜−〇)l= OH,の場合には、反応は例えば成る棟の金属ば化物( 飼えば遷移金属の酸化り、 瓶n04又はCra、)、又はメタ過ヨウ素戚塩、 それと例えば0s04 又は恥04 を触媒として用いた酸化によって行なわれ る。When X is C-~-〇)l=OH, the reaction is e.g. If kept, transition metal oxidation, Bottle n04 or Cra,) or metaperiodine related salts, Also, for example, oxidation using 0s04 or Shame04 as a catalyst is performed. Ru.
Yが一〇(SR)R,−Coo烏重の場合には、例えばラネーニッケル又は亜鉛 を酸性媒体中で用いることによる還元処理によって反応が行なわれる。If Y is 10 (SR) R, -Coo, for example, Raney nickel or zinc The reaction is carried out by reduction treatment using in an acidic medium.
Yが−c(on、+1−G■1−島の場合には、反応は水及び形成された酸を中 和するための弱塩基の存在下で行なわれる。もしX、がヨウ素の場合には、過酸 化物や例えば塩素のよ5な他の酸化剤で酸化することによシ反応を行なうのが有 利である。If Y is -c(on, +1-G It is carried out in the presence of a weak base for summing. If X is iodine, peracid It is useful to carry out the reaction by oxidizing with compounds or other oxidizing agents such as chlorine. It is advantageous.
Yが一〇〇−COORである場合には、反応は例えば触媒による還元及び水素化 分解によって行なわれる。If Y is 100-COOR, the reaction may include, for example, catalytic reduction and hydrogenation. This is done by decomposition.
一般タイブC 第3の一般タイブ、Cは以下の式 〔式中、鳥及び人は式(11中と同じ意味を有し、鳥から属、までは、そのうち の少なくとも1つが馬からRHO中の対応する基と同一でなく化学反応によって その対応する丞に変温し得るということを除いては、式(11の馬から馬、と同 じ意味を有する7 〕 の化合物を用いることを特徴とするものである。General type C The third general type, C, is the formula [In the formula, birds and humans have the same meaning as in 11, and from bird to genus, at least one of the groups is not identical to the corresponding group in RHO from the horse and is removed by chemical reaction. The same as the equation (11 horse to horse, 7 which has the same meaning It is characterized by using a compound of
鳥が水素原子の場合に絋、八が低級アルキルであるような化合物への変換はそれ 自体公知の方法によるアルキル化によって行なわれる。瓜、瓜及び鳥が水素原子 、シアノ、ヒドロキシ又はアミノ、及び少なくともそれらのうちの2つが水素原 子であるように選択されている場合は、その化合物は式+11で示される対応化 合物にそれ0坏公知の方法によるハロゲン化反応によって変換され得る。R,、 馬又は鶏がシアノの場合にはこの基はそれ自体公知の方法による加水分解によっ てカルボキシ(OOOH)に変換され得る。4掲又は艮のうちの1つ又は2つの 基がヒドロキシの場合にはそれ自体公知の方法によるアルキル化によってこれら の基はアルコキシに変換され得る。瓜、鶏又は鶏がアミンの場合にはそれ自体公 知の方法でジアゾ化され、続いてハロゲン塩又はシアナイド塩と反応することに よってハロゲン又はシアノに変換され得る。When the bird is a hydrogen atom, the conversion to a compound where the 狋 and 八 are lower alkyl is as follows. This is carried out by alkylation by methods known per se. Melon, melon and bird are hydrogen atoms , cyano, hydroxy or amino, and at least two of them are hydrogen atoms If selected to be a child, the compound has the correspondence given by formula +11. It can be converted into a compound by a halogenation reaction according to known methods. R,, If the horse or chicken is cyano, this group can be hydrolyzed by methods known per se. can be converted to carboxy (OOOH). One or two of the following four When the group is hydroxy, these can be obtained by alkylation by methods known per se. can be converted to alkoxy. If the melon, chicken, or chicken is an amine, it is itself public. diazotized by known methods and subsequently reacted with halogen salts or cyanide salts. Therefore, it can be converted to halogen or cyano.
同様にして、鵬から罠、もそれ自体公知で上述した方法に対応した反応型に従っ て新しい&からRltに変換され得る。Similarly, Peng to Trap also follows a reaction pattern that is known per se and corresponds to the method described above. can be converted from new & to Rlt.
一般タイブD 第4の一虹タイブ、Dは以下の式 〔式中、烏からRstf’:I式(1)中と同じ意味を有し、Xは式(1)中の 対応する基AK変換され得る基であるj〕の化合物を用いることを特徴とするも のである。には例えば、C(OR)t−1−cRx、−co−9−OR(OH) −’Sa−,−〇)LFL−OH(OH)−−−OH,−0FLX、−Co−で らυ、Bはハロゲン又は低級アルキル。General type D The fourth one rainbow type, D is the following formula [In the formula, Rstf': I has the same meaning as in formula (1), and X is It is also characterized in that it uses a compound of j] which is a group that can be converted into the corresponding group AK. It is. For example, C(OR)t-1-cRx, -co-9-OR(OH) -'Sa-, -〇)LFL-OH(OH)--OH, -0FLX, -Co- raυ, B is halogen or lower alkyl.
為はOH,ハロゲン又はエステル化アルコール性OHを示す。indicates OH, halogen or esterified alcoholic OH.
Xが一〇(OR)、−の場合、反応Fi酸性加水分解によって行なわれ架橋−C O−が形成する。When X is 10 (OR), -, the reaction Fi is carried out by acidic hydrolysis and the crosslinking -C O- forms.
Xが一〇RX、−co−の場合、還元水素化分解、好ましくはC−焉結合に特異 的な触媒水素化によって反応が行なわれ得る。When X is 10RX, -co-, reductive hydrogenolysis, preferably specific to the C-bond The reaction can be carried out by conventional catalytic hydrogenation.
A’$ −0R(0)1) −CHz −、−C肚−0H(OH)−又は−QH ,−C!RX。A'$ -0R(0)1) -CHz -, -C肚-0H(OH)- or -QH ,-C! RX.
−CO−の場合、H20又FiHX、を例えば酸又はアルカリ試薬と処理し除去 することによシ反応が行なわれる。In the case of -CO-, H20 or FiHX is removed by treatment with an acid or alkaline reagent, for example. By doing so, a reaction is carried out.
一般タイブE 第5の一改タイブ、Eは以下の式 〔式中、&から柘は式(1)中と同じ意味を有する/〕の化合物と以下の式 〔式中、鳥からR,までは式(1)中と同じ意味を有するノ〕の化合物を為とY 4とがお互いに反応して一人一基を形成するような方法で反応させることによっ て特徴づけられる。為とY4の組み合せの例としては以下のものが挙げられる。General type E The fifth revision type, E is the following formula [In the formula, & has the same meaning as in formula (1)] and the following formula [In the formula, from bird to R, have the same meanings as in formula (1)] By reacting in such a way that 4 and 4 react with each other to form one group per person. It is characterized by Examples of combinations of Y4 and Y4 include the following.
−CO−X、及びH又は、それぞれH及び−C!0−XI (XIはOH又はハ ロゲン);−CHt−Co−X、及びH;−cR=p(c、H,)m及びHCO −又は−COR及び((sHm )m P=CH−ニーCHO及び几−OH,− Co。-CO-X, and H or, respectively, H and -C! 0-XI (XI is OH or H -CHt-Co-X, and H; -cR=p(c,H,)m and HCO - or -COR and ((sHm )m P=CH-nee CHO and 几-OH, - Co.
もし該反応がアシル化反に;ttむような場合には、これらの反応は適当な#1 =、pg媒及び試薬例えばんtc4,5nC4,’I’iC4又はBF、のよう なものの存在下で行なわなければならない。If the reactions are similar to acylation reactions, these reactions can be carried out using the appropriate #1 reaction. =, pg media and reagents such as tc4, 5nC4, 'I'iC4 or BF, etc. It must be done in the presence of something.
−0HO及びR−CHt−Co−から−〇H=O几−CO−を形成する為には、 反応は例えば酸性又はアルカリ性触媒を溶媒の存在下で使用することによって行 ない得る。−0B−P (0sHi )s及びHCO−1又は−COR及び(C ,)(暮)、P=CB−から−0R=O)(−を形成するためにそれ自体公知の 方法で反応が行なわれる。To form -0H=O-CO- from -0HO and R-CHt-Co-, The reaction may be carried out, for example, by using an acidic or alkaline catalyst in the presence of a solvent. Not get. -0B-P (0sHi)s and HCO-1 or -COR and (C , ) (live), P=CB- to -0R=O) (known per se to form - The reaction is carried out in a method.
一般タイブF 第6の一般タイブ、Pは式(1)の化合物を以下の式の対応するラクトンに変換 するか、又は弐^1のラクトンを式(1)の化合物に変換するか、又はP4を別 なもう1つの烏に1換することを特徴とするものである。General type F The sixth general type, P converts the compound of formula (1) into the corresponding lactone of the formula or convert the lactone 2^1 into the compound of formula (1), or convert P4 to another compound. It is characterized by changing into another crow.
&がハロゲンの場合は、ラクトンへの変俣ri酸を用いた簡単な方法によって、 所望ならば脱水試薬、例えば無水酢酸若しくは塩化チオニA/、又は例えば水の 共握のように水を尿去する他の条件下に於いて行なわれる。鳥が低級アルキルの 場合は塩基によって反応が行なわれるが、生成したラクトンが対応する酸に加水 分解されないように注意しながら冥施する。When & is a halogen, by a simple method using modified ri acid to form a lactone, If desired, a dehydrating reagent such as acetic anhydride or thionichloride A/, or e.g. It is carried out under other conditions, such as co-gripping, where water is removed from the urine. bird is lower alkyl In this case, the reaction is carried out with a base, but the lactone produced is hydrated with the corresponding acid. Perform alms while being careful not to disintegrate.
本発明のラクトンはアルカリによる加水分解とそれにa < fR性化によって 対応する酸に直ちに変換し得る。又は、例えば鉱酸のようなば住触媒の存在下で 対応0アルコールと処理することによって対応するエステルに変換され得る。The lactone of the present invention is produced by hydrolysis with alkali and subsequent a<fR conversion. It can be readily converted to the corresponding acid. or in the presence of a basic catalyst such as a mineral acid. It can be converted to the corresponding ester by treatment with the corresponding alcohol.
島が水素厘子の場合は、該化合物はそれ自体公知の方法によるエステル化反応に よって鳥が低級アルキルであるような対応するエステルに変換し得る。If the island is a hydrogen cylinder, the compound can be subjected to an esterification reaction by a method known per se. Thus, it can be converted to the corresponding ester where avian is lower alkyl.
凡が低級アルキルの場合は、該化合物はそれ自体公知の方法によるアルカリ加水 分解とそれに続く酸性化によって対応する酸に変換し得る。When the compound is lower alkyl, the compound is alkaline hydrated by a method known per se. It can be converted to the corresponding acid by decomposition and subsequent acidification.
本発明の化合物を製造するに当って、一連の一般タイブλ〜Fに属する方法の2 つ以上を組み合せて中間生成物を単離することなく反応を同時に、又は次から次 へと直接的に連続して行なうようにすると、重要な利点をしばしば得ることがで きる。例えば、以下のように反応させることはしばしば有利なことである。In producing the compounds of the present invention, two of the methods belonging to a series of general types λ to F are used. Combine two or more reactions simultaneously or one after the other without isolating intermediate products. Significant advantages can often be obtained by following this in direct succession. Wear. For example, it is often advantageous to react as follows.
以下の化合物 を以下の化合物 〔式中、R及び鳥は低級アルキル、好ましくはメチルを表わ1へから馬、は式( 1)中と同じ意味を有する一〕と過剰んebtsの活性下で反応させ、アシy化 と同時に又はその直後に及び/又はワーク・アップ(work −up )の間 にR及びへ基を開裂させる。この反応は例えば以下の化合物、又は俣応牛〆対応 するエーテル(℃よシも反応中の反応性が非常に低い化合物である対応のラクト ンを用いて同じタイプの反応を実行した際に得られる収率に較べて高い収率を得 ることができる。The following compounds The following compounds [In the formula, R and R represent lower alkyl, preferably methyl; 1) React with 1] having the same meaning as inside under the activity of excess ebts to form acylation. At the same time or immediately after and/or during work-up to cleave the R and he groups. This reaction is applicable to, for example, the following compounds or The corresponding lactate is a compound with very low reactivity during the reaction. yields higher than those obtained when performing the same type of reaction using can be done.
鳥R1 同時反応のもう1つの例としては、以下の化合物〔式中、ル及び烏は式中(1) と同じ意味を有し、Rは低級アルキル、瓜から馬1のうちの1つの基は加水分解 され得る基、例えばシアナイド、カルボン酸エステル又はカルボン酸アミドのよ うなものを表わす7〕 を変換するものでちる。bird R1 As another example of simultaneous reaction, the following compound [wherein Ru and Karasu are (1)] has the same meaning as, R is lower alkyl, one group from melon to horse 1 is hydrolyzable groups such as cyanide, carboxylic esters or carboxylic amides. 7 to represent something It's something that converts.
瓜から罠、の中から選択される前記の加水分解され得る基は強鉱酸で処理するこ とによってカルボキシ7基に変換され得、同時にR及び&は任意に水素原子に置 換される。Said hydrolyzable groups selected from among gourds to traps can be treated with strong mineral acids. and at the same time, R and & are optionally placed on the hydrogen atom. will be replaced.
更にもう1つの例は加水分解され得る基の眩那水分解と同時にラクトンが形成さ れるものでるる。多数のこのような組み合わせに以下の多くの央凡例中で詳解さ nる。Yet another example is the formation of lactones simultaneously with the hydrolysis of hydrolyzable groups. There are things that can be done. A number of such combinations are detailed in the many central legends below. nru.
少なくとも1つの遊g7!ルボキシ基を含む本発明の化合物は、その化合物に適 した体で溶媒の存在下に於いて例えば水酸化ナトリウム、水酸化カリウム又は適 当な有機アミンのような適当な塩形成試薬(5alt −forming re agent )と反応させることによって対応する塩に直ちに変換し得る。At least one play g7! Compounds of the present invention containing a carboxy group are suitable for the compound. in the presence of a solvent, such as sodium hydroxide, potassium hydroxide or a suitable A suitable salt-forming reagent such as a suitable organic amine can be readily converted into the corresponding salt by reacting with the agent).
該塩はそれ自体公知の方法によって溶媒を除去し固体として調製され得るか、又 は直接に浴液中に(もし溶解できれば)、好ましくは水浴液中にその形態で直接 使用できるように調製される。The salt can be prepared as a solid by removing the solvent by methods known per se, or directly in the bath liquid (if it can be dissolved), preferably in that form directly in the water bath liquid. Prepared for use.
本発明の新規な医薬組成物は治療上有効量の式(1)の化合物又はそれのラクト ;/又は少、2くとも1つのカルボキシ7基を含む該化合物の塩を、所望に応じ て経口、直腸内又は腸管外投与にそれらは殺菌されるか及び/又は更にアジュバ ントを含むものでるる〇 【組成嘗は蛤業者に公知の方法により調製さn得る。活性物質を基剤物質及び任 意に更にアジュバントと混合し、得られた混合物をおる過当なガレニック形態( galenic form )に変涙する。投与量については、体重75胸の人 に1日当りlから1000■の範囲という一政的規定を与え得る◇本発明による popHmyのための新規な処方は、ヒトを含めた哺乳動物に治療上有効量の式 (+1の化合物、それのラクトン又は少なくとも1つのカルボキシ7基を含む該 化合物の塩を含む医薬組成物を投与することより成る。The novel pharmaceutical compositions of the present invention contain a therapeutically effective amount of a compound of formula (1) or a lactate thereof. ;/or a salt of the compound containing at least one carboxy 7 group, as desired. For oral, rectal or parenteral administration, they are sterilized and/or further adjuvanted. 〇 [The composition is prepared by methods known to those in the clam industry. Combining the active substance with the base substance Optionally, further mix with an adjuvant and fill the resulting mixture with a precipitated galenic form ( galenic form). For dosage, please refer to people weighing 75 breasts. ◇According to the present invention The new formulation for popHmy provides therapeutically effective doses of the formula to mammals, including humans. (+1 compounds, lactones thereof or compounds containing at least one carboxy 7 group) comprising administering a pharmaceutical composition comprising a salt of the compound.
以下の実施例は本発明の範囲を限定することなく本発明を詳 脱するものである 。The following examples serve to explain the invention in detail without limiting the scope of the invention. .
笑万例1 (a) ル 2− キシ−ベンゼン セーー2−メトキシーベンゼン酢酸500 gをメタノール4L及び硫酸(d=L84)150−に溶解する。この浴液を2 4時間沸騰させた後氷水上に注ぐ。クロロホルムで水相を抽出し、これを水及び 炭酸水素ナトリウムに対して振って混ぜ合せ、その後このクロロホルム溶液を蒸 発させる。lol million cases 1 (a) 2-methoxybenzene 2-methoxybenzene acetic acid 500 Dissolve g in 4 L of methanol and 150 − of sulfuric acid (d=L84). This bath liquid is 2 Boil for 4 hours and then pour over ice water. Extract the aqueous phase with chloroform and combine with water and Shake to mix against sodium bicarbonate, then evaporate this chloroform solution. make it emit
イル99を塩化メチレン65rJに溶解する。20分間に亘って塩化アルミニウ ム25gを還流下で少しずつ添加する。この混合物を坑井しながら22時間沸騰 させる0呈温に戻した後これを水上に注ぎ約300−のエーテルで抽出する。蒸 発転像後との残滓を1M水酸化ナトリウム200t/十エタノール200−で1 時間煮沸し加水分解する。この州を濃塩酸を用いて8に調節する。これを活性炭 処理し濾過した後、この溶液を約70℃にまで加熱し、塩酸を用いて国を約3に まで下げ生成物を沈澱させる。冷却後、生成物を戸別し水で況浄し乾燥させる。99 is dissolved in 65 rJ of methylene chloride. aluminum chloride for 20 minutes. 25 g of aluminum are added in portions under reflux. Boil this mixture for 22 hours in a well. After returning to 0 temperature, it is poured onto water and extracted with about 300 ml of ether. steaming The residue after image development was mixed with 200t of 1M sodium hydroxide/200t of ethanol. Boil for hours to hydrolyze. This state is adjusted to 8 using concentrated hydrochloric acid. Activated charcoal After treatment and filtration, the solution was heated to about 70°C and diluted with hydrochloric acid to about 3. to precipitate the product. After cooling, the product is taken from house to house, rinsed with water and dried.
NMRスペクトル及び元素分析のデータは表題化合物の構造と一致する。融点は 205℃であろう 実施例2 (a) メチル−2−ヒドロキシ−ベンゼンアセテート酢82−ヒドロキシ−ベ ンゼン250gをメタノール2を及び硫酸(d=L84)75−と伴1c24時 間沸騰させる◎この溶液を氷水上に注ぎクロロホルムで抽出する。このクロロホ ルム溶液を炭酸水素ナトリウムと水の溶液に対して振って混合しその後硫酸マグ ネシウムで脱水する。この溶液を蒸発させ、残滓を塩化メチレンに溶解し活性炭 で処理する。石油エーテル4QOwtを穏やかに熱しながらこの溶液に加える・ この浴液を一20℃まで冷却しその後結晶を戸別し石油エーテルで洗浄する。NMR spectra and elemental analysis data are consistent with the structure of the title compound. The melting point is It would be 205℃ Example 2 (a) Methyl-2-hydroxy-benzene acetate vinegar 82-hydroxy-benzene 250 g of 1c24 hr. Boil for a while. Pour this solution onto ice water and extract with chloroform. This chlorophore Shake the lume solution against the sodium bicarbonate and water solution, then mix with a sulfuric acid mug. Dehydrate with nesium. This solution was evaporated, the residue was dissolved in methylene chloride and activated charcoal was added. Process with. Add 4 Q Owt of petroleum ether to this solution with gentle heating. The bath liquid is cooled to -20°C, and the crystals are then separated and washed with petroleum ether.
(b)5−ベンゾイル−2−ヒドロキシ−ベンゼン=Sメチルー2−ヒドロキシ −ベンゼンアセテ−)IL6gと塩化ベンゾイル149をニトロベンゼンxoo *K11G解する。約10分間力)けて塩化アルミニウム279を少しずり添加 する・この溶液を60℃で24時間に拌する。冷却後、これを氷水及び塩酸上に 注ぐ。この混合物をクロロホルムで抽出しクロロホルム相を水蒸気蒸留する。蒸 留残滓を熱水で浸出しクロロポルムに溶解させて炭酸水素ナトリウム溶液に対し て振って混合させる。クロロホルム相を蒸発させ、その残滓を水酸化ナトリウム 2gを含む水100−中で1時間沸騰させる。メタノール100−をこの熱い溶 液に加え、これをギ酸で酸性化する。冷却後、生成物を炉別乾燥する。(b) 5-benzoyl-2-hydroxy-benzene = S methyl-2-hydroxy -Benzene acetate-) IL6g and benzoyl chloride 149 to nitrobenzene xoo *Understand K11G. Heat for about 10 minutes and add aluminum chloride 279 slightly. -Stir the solution at 60°C for 24 hours. After cooling, place it on ice water and hydrochloric acid. pour. This mixture is extracted with chloroform and the chloroform phase is steam distilled. steaming The residue was leached with hot water, dissolved in chloroporm, and then added to a sodium bicarbonate solution. Shake to mix. Evaporate the chloroform phase and dissolve the residue in sodium hydroxide. Boil for 1 hour in 100ml of water containing 2g. Add 100% of methanol to this hot solution. and acidify it with formic acid. After cooling, the product is oven dried.
NMRスペクトル及び元素分析のデータは表題化合物の構造と一致する。融点は 205℃である。NMR spectra and elemental analysis data are consistent with the structure of the title compound. The melting point is The temperature is 205°C.
実施例3 λ5−ジメチル安息香+ff159.クロロホルムzoow、塩化チオニルl〇 −及びジメチルホルムアミドIMtを、これ以上)1ctが発生しなくなるまで 沸騰する。この溶液を濃縮しメチル−2−メトキシ−ベンゼンアセテート169 及びニトロベンゼン100−と混合する。15分間かけて、塩化アルミニウム3 9gを少しずつ添加し、このフラスコを18時間約55℃に維持する。この溶液 を水冷塩酸上に注ぎクロロホルムで抽出する。Example 3 λ5-dimethylbenzoin+ff159. Chloroform zoow, thionyl chloride l〇 - and dimethylformamide IMt until no more) 1 ct is generated. Boil. This solution was concentrated and methyl-2-methoxy-benzene acetate 169 and nitrobenzene 100-. aluminum chloride over 15 minutes Add 9 g in portions and maintain the flask at approximately 55° C. for 18 hours. This solution Pour onto water-cooled hydrochloric acid and extract with chloroform.
このクロロホルム相を水洗し水蒸気蒸留し、その残滓を1M水酸化ナトリウム2 0〇−及びエタノール20ゴ中で加水分解される。−を約7に調節しこの溶液を クロロホルムに対して振って混合する。これを蒸発濃縮し冷却後2&5gの結晶 沈設物を得る。この結晶をエタノール100−及び水400−に溶解し酢酸を添 加すると表題の酸が結晶化する。This chloroform phase was washed with water and steam distilled, and the residue was extracted with 1M sodium hydroxide. It is hydrolyzed in 00- and ethanol 20-g. - to about 7 and add this solution to Mix by shaking against chloroform. After evaporating and concentrating this and cooling, 2&5g of crystals Obtain deposits. The crystals were dissolved in 100% of ethanol and 400% of water, and acetic acid was added. When added, the title acid crystallizes.
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。NMR spectrum and elemental analysis data are consistent with the structure of the title compound.
(b) 5− 3.5−ジメチル−ベンゾイル −2−ヒドロキシ−ベンゼン酢 酸 5−(λ5−ジメチルベンゾイル)−2−メトキシ−ベンゼン酢酸10 g、美 化水素酸(酢酸中で40 w / v%)40−。(b) 5-3.5-dimethyl-benzoyl-2-hydroxy-benzene vinegar acid 5-(λ5-dimethylbenzoyl)-2-methoxy-benzeneacetic acid 10 g, beauty Hydrohydric acid (40 w/v% in acetic acid) 40-.
水15−及びヨウ化水素酸2−を24時間還流させる。冷却後、この溶液を水上 に注ぐ。沈澱物を戸別し2M水酸化ナトリウム溶液100Nt中で煮沸しその抜 水60〇−及びエタノ−#100−でこれを希釈する。声を約7に調節し、この 溶液を活性炭処理しその沸点まで加熱する・酢酸を加える。溶液から沈澱した結 晶を戸別し酢酸中に溶解し活性炭処理する。この溶液に水を加えると生成物が結 晶化する。これを酢酸から再結晶化させる。Water 15- and hydroiodic acid 2- are refluxed for 24 hours. After cooling, pour this solution over water. Pour into. The precipitate was taken from house to house and boiled in 100Nt of 2M sodium hydroxide solution. Dilute this with 600ml of water and #100 of ethanol. Adjust your voice to about 7 and use this Treat the solution with activated carbon and heat to its boiling point. Add acetic acid. The crystals precipitated from the solution. The crystals are taken one by one, dissolved in acetic acid, and treated with activated carbon. Adding water to this solution causes the product to condense. crystallize. This is recrystallized from acetic acid.
NMRスペクトラムと元素分析のデータは表題化合物の構造と一致する。融点は 242℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. The melting point is The temperature is 242°C.
実施例4 4−(2−7二二ルー1−エテニ/l/ ) −フェノール19.6g。Example 4 19.6 g of 4-(2-722-1-ethenyl/l/)-phenol.
ベンゼンボロン酸146g、プロピオン酸18g及びトルエン100−を水分離 器を用いて還流する。Water separation of 146 g of benzene boronic acid, 18 g of propionic acid and 100 g of toluene Reflux using a container.
L5時間かけてバラホルムアルデヒド12.0gを少しずつ添加する。この混合 物をもう1時間沸騰させる。室温まで冷却した後、エーテル100−を加え結晶 化した生成物を戸別しエーテルで洗浄する。12.0 g of rose formaldehyde is added in portions over a period of 5 hours. This mixture Let things boil for another hour. After cooling to room temperature, add ether 100- and crystallize. The resulting product is washed with ether.
−宇に懸次させる。約1o分間かけて30%W / Wの過酸化水素325ゴを 攪拌しながら少しずつ添加し室温まで冷却する。− Make U work hard. Add 325 grams of hydrogen peroxide at 30% W/W for about 10 minutes. Add portionwise while stirring and cool to room temperature.
この反応混合物を20分間放置した後氷水上に注ぎ、その後生じた沈澱生成物を 戸別し水洗する。The reaction mixture was allowed to stand for 20 minutes and then poured onto ice water, after which the precipitated product formed was Wash each door with water.
(c)2−ヒドロキシ−5−2−フェニル−1−エチニル −ご32お企匪虞− 2−ヒドロキシ−5−(2−)モー〃−1−エチニル)−ベンゼンメタノール9 .19及びシアン化カリウム&15gをジメチルホルムアミド12〇−中で24 時間120’Cで熱する。水20ゴを加え水酸化ナトリウムで虜を約101C調 節する。この溶液を蒸発乾燥する。残滓を水50−に溶解する。この溶液を酢酸 で中和しエーテルで数回抽出する。数回水洗した後、このエーテル相を蒸発乾燥 させる。(c) 2-Hydroxy-5-2-phenyl-1-ethynyl 2-Hydroxy-5-(2-)mo-1-ethynyl)-benzene methanol 9 .. 19 and potassium cyanide &15g in dimethylformamide 120-24 Heat at 120'C for an hour. Add 20 grams of water and adjust to about 101C with sodium hydroxide. make a clause This solution is evaporated to dryness. Dissolve the residue in 50°C of water. Add this solution to acetic acid Neutralize with water and extract several times with ether. After washing several times with water, this ether phase was evaporated to dryness. let
この残滓を水10−及び#C硫酸7−中で6時間沸騰させて加水分解する。この 溶液を水で希釈しエーテルで抽出する。アル−チルで抽出し直す。乾燥濃縮後、 生成化合物を酸を用いたアルカリからの再沈澱をab返して樗製しアセトン及び 石油エーテルから再結晶化するつ NMRMペクトラム及び分素分析のデータは表題化合物の構造と一致する。融点 は202℃である。The residue is hydrolyzed by boiling for 6 hours in 10 - of water and 7 - of #C sulfuric acid. this The solution is diluted with water and extracted with ether. Extract again with alkyl. After drying and concentration, The resulting compound was reprecipitated from an alkali using an acid, and then made from oak, and then mixed with acetone and Recrystallized from petroleum ether NMRM spectra and fractional analysis data are consistent with the structure of the title compound. melting point is 202°C.
実施例5 2−ヒドロキシ−5−(4−クロコベンソイル)−ベンゼン酢酸 4−クコロペンゾイy クロリド17.59及びメチル 2−ヒドロキシーペン ゼンアセテゴ÷iトロベンゼン10 ()iK溶解する。約20分間かげて塩化 アルミニウム279を少しずつ添加する。この溶液を16時間60℃に維持し、 その後氷塩酸上に注ぐ。この混合物をクロロホルムで抽出し、このクロロホルム 相を水蒸気蒸留する。蒸留残滓をクロロホルムに溶解し活性炭処理し炭酸水素ナ トリウムの溶液に対1−て振って混合する。クロロホルム溶液を蒸発させ、残っ たオイルを石油エーテル−ベンゼンと僕71し生じた結晶を戸別する。この結晶 を水酸化ナトリウム4gを含む水10〇−中で1時間沸騰し肌水分解し、塩酸を 結晶が沈澱し始めるまで滴下する。め却後生成物を融点は250℃である。Example 5 2-Hydroxy-5-(4-crocobenzoyl)-benzeneacetic acid 4-Cucoropenzoy chloride 17.59 and methyl 2-hydroxypene Zenacetego÷itrobenzene 10 ()iK dissolve. Salt for about 20 minutes Add aluminum 279 little by little. The solution was maintained at 60°C for 16 hours, Then pour over glacial hydrochloric acid. This mixture was extracted with chloroform, and the chloroform The phase is steam distilled. The distillation residue was dissolved in chloroform, treated with activated carbon, and dissolved in hydrogen carbonate. Shake to mix 1:1 in the thorium solution. Evaporate the chloroform solution and leave the remaining The oil was mixed with petroleum ether-benzene and the resulting crystals were separated. this crystal Boil it in 100ml of water containing 4g of sodium hydroxide for 1 hour to decompose the skin water and remove hydrochloric acid. Add dropwise until crystals begin to precipitate. The melting point of the product after discarding is 250°C.
実施例6 5−4−シアノベンゾイル)−2−ヒドロキシ−ベンゼン酢4− シフ / 安 息香酸14rg、クロロホルム100ゴ、塩化チオニル10ゴ及びジメチルホル ムアミドo、25ゴを6時間沸騰させる。この溶液を蒸発させ、その残滓をニト ロベンゼン100rILtに溶解し、メチル 2−ヒドロキシ−ベンゼンアセテ −)1&6りを加え、その後約20分間かけて塩化アルミニウム409を少しず つ加える。この溶液を8時間50℃に維持し、その後こnを氷塩酸上に注ぐ。こ の混合物をエーテルで抽出しこのエーテル相を蒸発させる。このオイルを水蒸気 蒸留にかけその残滓をクロロホルムで抽出し、その後このクーロホルム溶液を硫 酸マグネシウムで脱水し活性炭処理する。このクロロホルム湛液を蒸発させ、残 滓をエタノール約50+dK溶解し声10の水酸化カリウム浴液100−やで加 水分解する。得られた溶液を0.5!、まで希釈しギ酸で酸性化する。生成物は 結晶化し、これを戸別乾燥させる。Example 6 5-4-cyanobenzoyl)-2-hydroxy-benzene vinegar 4-Schiff/An 14g of zoic acid, 100g of chloroform, 10g of thionyl chloride and dimethylform. Boil Muamido o, 25 go for 6 hours. Evaporate this solution and nitrate the residue. Dissolved in lobenzene 100rILt, methyl 2-hydroxy-benzene acetate -) Add aluminum chloride 409 for about 20 minutes. Add one. The solution is kept at 50° C. for 8 hours and then poured onto glacial hydrochloric acid. child The mixture is extracted with ether and the ether phase is evaporated. steam this oil The residue was extracted with chloroform, and the chloroform solution was then distilled with sulfuric acid. Dehydrate with magnesium acid and treat with activated carbon. Evaporate this chloroform solution and Dissolve the slag in ethanol at about 50 + dK and add it to 100 - dK potassium hydroxide bath solution. Splits water. The resulting solution is 0.5! , and acidify with formic acid. The product is It crystallizes and is dried from door to door.
NM凡ススペクトラムび元素分析のデータは表題化合物の荷造と一致する。融点 1218℃である。The NM spectrum and elemental analysis data are consistent with the design of the title compound. melting point The temperature is 1218°C.
笑嵩例7 2−ヒ)”E:I’l”−5−4−カルボキシベンゾイル −ベンゼ5−(4− シアノベンゾイル)−2−ヒドロキシ−ベンゼン酢酸29を酸920d、水1〇 −及び硫酸10ゴ中で24時間沸騰させる。この溶液を室温まで冷却する。沈殿 を戸別しこれを水洗する。この沈澱を1M水酸化カリウム溶液中で18時間沸騰 させる。この溶液をギ酸で酸性化し冷却する。こうして結晶化した生成物を炉別 し水洗し乾燥する。Laughing example 7 2-hi)"E:I'l"-5-4-carboxybenzoyl-benze5-(4- cyanobenzoyl)-2-hydroxy-benzeneacetic acid 29, acid 920d, water 10 - and boil in sulfuric acid for 24 hours. Cool the solution to room temperature. precipitation Go door to door and wash it with water. This precipitate was boiled in 1M potassium hydroxide solution for 18 hours. let The solution is acidified with formic acid and cooled. The product thus crystallized is separated into furnaces. Wash with water and dry.
NMRMペクトラム及び元累分析のデータは表題化合物の構造と一致する。融点 は260℃よう高い。NMRM spectra and cumulative analysis data are consistent with the structure of the title compound. melting point The temperature is as high as 260℃.
実施例8 4−シアノ安息香酸10り、塩化チオニル8ゴ、ジメチルホルムアミド0.5− 及びクロロホルム100−を16時間沸騰させその後蒸発させる。Example 8 4-cyanobenzoic acid 10, thionyl chloride 8, dimethylformamide 0.5- and chloroform 100- are boiled for 16 hours and then evaporated.
塩化アルミニウム35gをニトロベンゼン80ss!に溶解させる。これに該酸 の塩化物及びメチル2−メトキシベンゼンア七チー)17−29を溶解させた2 0−のニトロベンゼンヲ添加する。この溶液を60℃で24時間維持し、その後 こnを氷水上に注ぎ塩化メチレンで抽出する。この塩化メチレン相を希釈塩酸及 び水に対して振って混合する。これを濃縮し石油エーテルで希釈する。結晶を戸 別しエタノールから再結晶化きせる。35g of aluminum chloride and 80ss of nitrobenzene! Dissolve in. This acid chloride and methyl 2-methoxybenzeneyl chloride 17-29 Add 0-nitrobenzene. This solution was maintained at 60°C for 24 hours, then The mixture was poured onto ice water and extracted with methylene chloride. This methylene chloride phase is diluted with hydrochloric acid and Mix by shaking against water. This is concentrated and diluted with petroleum ether. crystal door Separate and recrystallize from ethanol.
メチル15−(4−シアノベンゾイル)−2−メトキシ−ベンゼンアセテート1 0gを40%W/W臭化水素(酢酸中)Rood、水30−及びヨウ化水素2I ILt中で24時間沸騰させる。この溶液を水上に注ぎ沈澱を戸別し、母液を酢 酸エチルで抽出し蒸発し沈澱と一緒にプールする。生成物を30分間α5M水酸 化ナトリウム溶液中で沸騰させ、≠を酢酸で約6に調節し、この溶液を活性炭処 理する。その後これを約70℃に加熱し、ギ酸を加え生成物を結晶化させ始め、 そうしてこの溶液を冷却する。生成物を戸別し水洗乾燥する。Methyl 15-(4-cyanobenzoyl)-2-methoxy-benzene acetate 1 0 g to 40% W/W hydrogen bromide (in acetic acid) Rood, water 30- and hydrogen iodide 2I Boil in ILt for 24 hours. Pour this solution over water, separate the precipitate, and soak the mother liquor in vinegar. Extract with ethyl acetate, evaporate and pool together with the precipitate. The product was treated with α5M hydroxyl for 30 minutes. ≠ was adjusted to about 6 with acetic acid, and the solution was treated with activated carbon. Understand. This was then heated to about 70°C, and formic acid was added to begin crystallizing the product. The solution is then cooled. The product is washed and dried separately.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は260℃よフ高いつ実施例9 5−ベンシイA/ −3−プロモー2−ヒドロキシ−ベンゼン酢酸5−ベンゾイ ル−2−ヒドロキシ−ベンゼン酢酸13り及び酢酸ナトリウム5gをテトラヒド ロ7ラン15011ItK溶解する。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point Example 9 5-benzoy A/-3-promo 2-hydroxy-benzeneacetic acid 5-benzoy 13-2-hydroxy-benzeneacetic acid and 5 g of sodium acetate were added to tetrahydrochloride. Dissolve Ro7 Run 15011ItK.
約1時間かけてこれにテトラヒドロ7ラン50wtK溶解した1(lの臭素を滴 下する。この溶液を蒸発させ、その後残滓を少量のメタノールに溶解する。この メタノール溶層を硫酸で酸性化し戸別する。この浴部を150dのメタノールで 希釈する。1 (l) of bromine dissolved in 50 wtK of tetrahydro7ran was added dropwise to this solution over a period of about 1 hour. down. The solution is evaporated and the residue is then dissolved in a small amount of methanol. this Acidify the methanol solution layer with sulfuric acid and distribute it from house to house. This bath part was heated with 150d of methanol. Dilute.
硫酸20−を添加し、その後この溶液を18時間沸騰させる。20 ml of sulfuric acid is added and the solution is then boiled for 18 hours.
これを氷水上に注ぎベンゼンで抽出しベンゼン−インオクタンから再結晶化させ る0この生成物をメタノール−水から2回再結晶化させIM水水化化ナトリウム 溶液中加水分解する。得られる溶液を塩酸で酸性化し、クロロホルムで抽出し、 硫酸マグネシウムで脱水し蒸発する。残滓をベンゼン−イソオクタンから再結晶 化させる。生成物を戸別し乾燥する。This was poured onto ice water, extracted with benzene, and recrystallized from benzene-in-octane. This product was recrystallized twice from methanol-water to IM sodium hydrate. Hydrolyzes in solution. The resulting solution was acidified with hydrochloric acid, extracted with chloroform, Dehydrate with magnesium sulfate and evaporate. Recrystallize the residue from benzene-isooctane to become Dry the product from house to house.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は132℃である、実施例10 2−7 k オ* 安JliFR14g、クロロホルムlo oat、 [化チ オニル10m及びジメチルホルムアミド1−を6時間沸騰す・18g及び塩化メ チレン50−と混合し、この混合物を50gの塩化アルミニウムを含む塩化メチ レン1s o*ois物中に筒下し、これを6時間沸騰させた。この溶液を氷水 上に注ぎ、クロロホルムで抽出し、硫酸マグネシウムで脱水し、活性炭処理Li dさせる 残滓をベンゼン−イソオクタンから再結晶化させる。生成物を水酸化 す) IJウム300ゴ中で加水分解し、この熱い溶液を酢酸で酸性化する。生 成物が結晶化し始めたら溶液を冷却し、生成物を戸別する。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 132°C, Example 10 2-7 k O* AnJliFR14g, chloroform loat, [chemical Boil 10m of onyl and dimethylformamide 1- for 6 hours. 18g and dimethylformamide. 50 g of tyrene, and the mixture was mixed with methyl chloride containing 50 g of aluminum chloride. The mixture was poured into a glass of water and boiled for 6 hours. Pour this solution into ice water poured on top, extracted with chloroform, dehydrated with magnesium sulfate, and treated with activated carbon. d The residue is recrystallized from benzene-isooctane. hydroxylate the product ) Hydrolyze in IJum 300g and acidify the hot solution with acetic acid. Living Once the product begins to crystallize, the solution is cooled and the product is distributed.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は102℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 102°C.
実施例11 5− λ+−ジクロロベンゾイル −2−ヒドロキシ−ベンゼン酢酸 実施例1Oと同様の方法で本合成を実施する◇NMRスペクトラム及び元素分析 のデータは表題化合物の構造と一致する。融点は226℃である。Example 11 5-λ+-dichlorobenzoyl-2-hydroxy-benzeneacetic acid This synthesis is carried out in the same manner as in Example 1O. ◇NMR spectrum and elemental analysis The data are consistent with the structure of the title compound. The melting point is 226°C.
実施例12 実施例10と同様の方法で本合成を実施する。Example 12 This synthesis is carried out in the same manner as in Example 10.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は171℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 171°C.
実施例13 5−ベンゾイル−2−ヒドロキシ−3−クロロ−ベンゼン酢酸メチル5−ベンゾ イル−2−ヒドロキシ−ベンゼンアセテ−)IL39.N−クロロサクシニ=ド S、7g及びクロロホルム10011/を18時間′a騰する。この懸濁液を蒸 発し、ベンゼンに溶解し水に対して振って混合させる。ベンゼン溶液を乾燥蒸発 すせる。残滓をベンゼン−イソオクタン711)も再結晶化させる。Example 13 5-benzoyl-2-hydroxy-3-chloro-benzene methyl acetate 5-benzo IL39. N-chlorosuccinid 7 g of S and 10011/ml of chloroform are boiled for 18 hours'a. Steam this suspension. Emit, dissolve in benzene and shake against water to mix. Dry evaporation of benzene solution Slow down. The residue is also recrystallized from benzene-isooctane 711).
生成物を水酸化ナトリウム中で1時間沸騰させ、その後こうし、。The product was boiled in sodium hydroxide for 1 hour;
て得られた溶液を塩酸で酸性化する。その後、この溶液を冷却し、生成物を戸別 し乾燥する− NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は131℃である。The solution obtained is acidified with hydrochloric acid. This solution is then cooled and the product is distributed door to door. and dry. NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 131°C.
実施例14 メチル 2−ヒドロキシ−ベンゼンアセテート1a6g及びフェニルアセチルク ロ2イドIL4gをニトロベンゼン100ゴに溶解する。室温で塩化アルミニウ ム279を少しずつ加え、その後この溶液を60℃にて8時間維持する。その後 これを氷塩酸上に注ぎクロロホルムで抽出する。このクロロホルム溶液を水蒸気 蒸留しその残滓を沸騰する水酸化ナトリウム中でm水分解する。−i7にv4節 し溶液をクロロホルムで抽出する。Example 14 Methyl 2-hydroxy-benzene acetate 1a6g and phenylacetyl Dissolve 4 g of 2D IL in 100 g of nitrobenzene. Aluminum chloride at room temperature Moum 279 is added in portions and the solution is then maintained at 60° C. for 8 hours. after that This is poured onto glacial hydrochloric acid and extracted with chloroform. Steam this chloroform solution Distill and the residue is water split in boiling sodium hydroxide. -i7 to v4 clause The solution is extracted with chloroform.
水相を塩酸で酸性化しその後生ずる結晶を戸別乾燥する・この生成物をエチルメ チルケトン−クロロホルムから再結晶化させる。The aqueous phase is acidified with hydrochloric acid, and the resulting crystals are then dried door to door.This product is Recrystallize from tilketone-chloroform.
NMRスペクト2ム及び元素分析のデータは表題化合物の構造と一致する。融点 は198℃でちる。NMR spectra and elemental analysis data are consistent with the structure of the title compound. melting point Chill at 198℃.
実施例15 (、) メチル 5−(2−(4−シアノフェニル)−アセチル)−2−メトキ シ−ベンゼンアセテート 4−シアノ−ベンゼン酢酸1&29.塩化チオニル12ゴ。Example 15 (,) Methyl 5-(2-(4-cyanophenyl)-acetyl)-2-methoxy seabenzene acetate 4-cyano-benzeneacetic acid 1&29. Thionyl chloride 12g.
クロロホルム10〇−及びジメチルホルムアミドα511ttを4時間沸騰させ る。溶液を蒸発させ、残滓をメチ/I/ −2−メトキシ−ベンゼンアセテート 2α3gを含む塩化メチレンsoyKm解する。この溶液を塩化鉛60sdを含 む塩化メチレン25〇−溶液に滴下して加える。この溶液を18時間沸騰させ、 氷水上に注ぎクロロホルムで抽出する。このクロロホルム相を硫酸マグネシウム で脱水し活性炭処理し蒸発させる。残滓をエタノールから2回再結晶化させる。Boil chloroform 100- and dimethylformamide α511tt for 4 hours. Ru. The solution was evaporated and the residue was purified with methi/I/-2-methoxy-benzene acetate. Solve methylene chloride soyKm containing 2α3g. This solution contains 60sd of lead chloride. Add dropwise to a 250% methylene chloride solution. Boil this solution for 18 hours, Pour onto ice water and extract with chloroform. This chloroform phase is mixed with magnesium sulfate. Dehydrated, treated with activated carbon and evaporated. The residue is recrystallized twice from ethanol.
(b)2−ヒドロキシ−5−(2−(4−カルボキシフェニル)−アセチ/I/ )−ベンゼン酢酸 致するっ融点は260℃よシ高い。(b) 2-hydroxy-5-(2-(4-carboxyphenyl)-acety/I/ )-benzeneacetic acid Its melting point is higher than 260°C.
実施例16 メチル2−メトキシ−ベンゼンアセテート36g及び塩化アセチル1&79を塩 化メチレン100ゴに溶解し、得られる溶液を塩化アルミニウム1009を含む 塩化メチレン300−に滴下する。この溶液を5時間3悌させ氷水上に注ぎ戸別 する。Example 16 36 g of methyl 2-methoxy-benzene acetate and acetyl chloride 1 & 79 are salted. Dissolve 100% of methylene chloride in the resulting solution containing 100% of aluminum chloride. Add dropwise to 300 methylene chloride. This solution was left to stand for 3 hours for 5 hours, and then poured over ice water. do.
結晶を水と塩化メチレンで洗浄するコ (b)5−(3−)二ニルー1−オキソー2−プロペニル)−2−ヒドロキシ− ベンゼン酢酸 メチル5−7セテルー2−ヒドロキシ−ベンゼンアセテートlα<9.ベンズア ルデヒド5.3g、5M水酸化ナトリウム5〇−及びエタノ−/l15011I tを4時間アイスバス中で攪拌し、次いで室温にて20時間攪拌するっこの溶液 を水150ゴで希釈し、酢酸を滴下する。Cleaning the crystals with water and methylene chloride (b) 5-(3-)dinyl-1-oxo-2-propenyl)-2-hydroxy- benzene acetic acid Methyl 5-7ceteru-2-hydroxy-benzene acetate lα<9. benzua 5.3 g of aldehyde, 5M sodium hydroxide and ethanol/l 15011I This solution is stirred in an ice bath for 4 hours and then for 20 hours at room temperature. Dilute with 150 g of water and add acetic acid dropwise.
沈澱を戸別乾燥する。これをエチルメチルケトレーベンゼンかう再結晶化させて 乾燥する。Dry the precipitate door to door. This was recrystallized with ethyl methyl ketorebenzene. dry.
NMRスペクトラム及び元素分析のデータは表聰化合物の4造と一致する。融点 は198℃でちるO実施例17 2−ヒドロキシ−5−3−4−カルボキシフェニル −1−オキソ−2−プロペ ニル −ベンゼン本合成は実施例1s[b)と同様に実施するONM凡スペクト ラム及び元素分析のデータは表題化合物の構造と一致する。融点は260℃よシ 高い。The NMR spectrum and elemental analysis data are consistent with the four-form structure of the compound. melting point Chilled at 198°C Example 17 2-hydroxy-5-3-4-carboxyphenyl-1-oxo-2-prope The main synthesis of nyl-benzene was carried out in the same manner as in Example 1s [b). Lamb and elemental analysis data are consistent with the structure of the title compound. Melting point is around 260℃ expensive.
実施例18 3−シアノ安息香酸147g、クロロホルム40d、塩化チオニル10−及びジ メチルホルムアミドα2−を18時間沸騰させる。Example 18 147 g of 3-cyanobenzoic acid, 40 d of chloroform, 10- and di-thionyl chloride Boil methylformamide α2- for 18 hours.
この溶液を濃縮しその後メチ/l/2−メトキシ−ベンゼンアセテ−)7.39 及び塩化メチレン20−と混合する。得られた溶液を塩化メチレン10Qd中の 塩化スズ24−の溶液に加え全体を48時間沸騰させる。この浴液を氷水上に注 ぎ、クロロホルムで抽出し、活性炭処理し蒸発させる、残滓を少量のエタノール で浸出(1eech )させメタノール−水から再結晶化させる。This solution was concentrated and then methi/l/2-methoxy-benzene acetate)7.39 and methylene chloride 20-. The resulting solution was dissolved in 10Qd methylene chloride. Add to the solution of 24 - of tin chloride and boil the whole for 48 hours. Pour this bath solution onto ice water. extracted with chloroform, treated with activated carbon, evaporated, and the residue was dissolved in a small amount of ethanol. and recrystallize from methanol-water.
本合成は実施例8とF3様に実施する。The synthesis is carried out as in Example 8 and F3.
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は260℃より高い。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is higher than 260°C.
実施例19 メチル2−ヒドロキシ−5−(2−/+30ペンシイ/L/)−ベンゼンアセテ ート 2−クロロ安息香酸15.69.塩化チオニル10−2塩化メfレン150 m g及びジメチルホルムアミドQ、5a!を塩化水素ガスの発生が止むまで沸騰す る。この溶液を蒸発させ、残滓をメチ、It/−2−メトキシ−ベンゼンアセテ −)189を含む塩化メチレン50−に溶解する。この溶液を塩化アルミニウム 509を含む塩化メチレン200ゴに滴下し16時間沸騰させる。この溶液を氷 水上に注き゛、クロロホルムで抽出し、乾燥し活性炭処理する。その後蒸発させ 残滓をベンゼン−石油エーテルに溶解し活性炭処理する。更に石油エーテルを加 え結晶を沈澱させるO NMRスペクトラム及び元素分析のデータは表題化合物の4造と一致する。融点 は119℃である。Example 19 Methyl 2-hydroxy-5-(2-/+30 pence/L/)-benzeneacetate root 2-chlorobenzoic acid 15.69. Thionyl chloride 10-2 melene chloride 150m g and dimethylformamide Q, 5a! Boil until the generation of hydrogen chloride gas stops. Ru. The solution was evaporated and the residue was dissolved in methoxy, It/-2-methoxy-benzene acetate. -) 189 in methylene chloride containing 50-. Add this solution to aluminum chloride The mixture was added dropwise to 200 g of methylene chloride containing 509 and boiled for 16 hours. Put this solution on ice. Pour over water, extract with chloroform, dry and treat with activated charcoal. then evaporate The residue is dissolved in benzene-petroleum ether and treated with activated carbon. Add petroleum ether O to precipitate crystals The NMR spectrum and elemental analysis data are consistent with the 4 structure of the title compound. melting point is 119°C.
実施例20 メチル−5−(4−フルオロベンゾイル)−2−ヒドロキシ−ベンゼンアセテー ト 本合成Vi冥施例19と同様に実施する。Example 20 Methyl-5-(4-fluorobenzoyl)-2-hydroxy-benzene acetate to This synthesis is carried out in the same manner as in Example 19.
NMR及び元素分析のデータは表題化合物の構造と一致する。NMR and elemental analysis data are consistent with the structure of the title compound.
触点は173℃である。The touch point is 173°C.
実施例21 s−(4−フルオロベンゾイル)−2−ヒドロキシ−ベンゼン酢酸 メチル5−(4−フルオロペンシイ/I/) −2−ヒドロキシ−ベンゼンアセ テ−)15gをα5M水酸化ナトリウム300d及びエタノール1〇−中で15 分間沸騰させる。−を塩酸で約7に調節し、この熱い溶液を酢酸で酸性化する。Example 21 s-(4-fluorobenzoyl)-2-hydroxy-benzeneacetic acid Methyl 5-(4-fluoropency/I/)-2-hydroxy-benzeneacetic acid T) 15g in α5M sodium hydroxide 300d and ethanol 10-15g Boil for a minute. - is adjusted to about 7 with hydrochloric acid and the hot solution is acidified with acetic acid.
この溶液を約40℃まで冷ヰする。結晶を戸別し水洗する。Cool this solution to about 40°C. The crystals are washed door to door with water.
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は218℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 218°C.
実施例22 (a) メチル5−(2−(2−フルオロ−6−クロロフェニル)−アセチル) −2−ヒドロキシ−ベンゼンアセテート本合成は実施例19と同様に実施する。Example 22 (a) Methyl 5-(2-(2-fluoro-6-chlorophenyl)-acetyl) -2-Hydroxy-benzene acetate The main synthesis is carried out analogously to Example 19.
アセチル)−2−ヒドロキシベンゼントヨ虹本合成は実施例21と同様に実施す る。The synthesis of acetyl)-2-hydroxybenzene was carried out in the same manner as in Example 21. Ru.
NMRスペクトラム及び元素分析のデータ(1表題化合物の構造と一致する。融 点は240℃である。NMR spectrum and elemental analysis data (1 Consistent with the structure of the title compound. The point is 240°C.
実施例23 2−クロロ−ベンゼン酢酸179.塩化チオニル10m、ジメチルホルムアミド (L5−及び塩化メチレン150−を6時間沸騰させる。この溶液を蒸発させ、 残滓をメチル2−メトキシ−ベンセンアセテート18gを含む塩化メチレン5o −に溶解させる。得ら几た溶液を塩化鉛50sdを含む塩化メ、チレン250ゴ に滴下し加える。この溶液を24時間沸騰させ、氷水上に注ぎ、クロロホルムで 抽出し、乾燥し活性炭で処理する◇このクロロホルム溶液を蒸発させ、残滓をエ タノールがら再結晶化させる。IM水酸化ナトリウム200m中でこの結晶を加 水分解し水とエタノール5o−dで約300−まで希釈し、その後この溶液を沸 騰させながら酢酸で酸性化する。その後、冷却し結晶を戸別する。Example 23 2-Chloro-benzeneacetic acid 179. Thionyl chloride 10m, dimethylformamide (L5- and methylene chloride 150- are boiled for 6 hours. The solution is evaporated and The residue was dissolved in 50 methylene chloride containing 18 g of methyl 2-methoxy-benzene acetate. - dissolve in The resulting diluted solution was mixed with methane chloride containing 50 sd of lead chloride and 250 g of tyrene. Add dropwise. The solution was boiled for 24 hours, poured onto ice water, and diluted with chloroform. Extract, dry and treat with activated carbon ◇ Evaporate this chloroform solution and evaporate the residue. Recrystallize from tanol. The crystals were dissolved in 200 m of IM sodium hydroxide. Water was decomposed and diluted with water and ethanol 5o-d to about 300-d, then this solution was boiled. Acidify with acetic acid while boiling. After that, it is cooled and the crystals are distributed from house to house.
(b)2−ヒドロキシ−5−(2−(2−クロロフェニル)−ア本合成は実施例 3(b)と同様に実施する。(b) 2-hydroxy-5-(2-(2-chlorophenyl)-a This synthesis is an example Perform the same procedure as in 3(b).
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は230℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 230°C.
実施例24 本合成は実施例16ib)と同様に実施する。Example 24 The synthesis is carried out analogously to Example 16ib).
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は212℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 212°C.
実施例25 本合底ri夷天例23(alと同様に実施する。Example 25 This is carried out in the same manner as Example 23 (al).
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は187℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 187°C.
本合成は実施例3(b)と同様に実施する。This synthesis is carried out in the same manner as in Example 3(b).
致する06点は120℃である。The matching point 06 is 120°C.
実施例26 5−(2−クロロベンゾイル −2−ヒドロキシ−ベンゼン酢NMRスペクトラ ム及び元素分析のデータは表題化合物の宿−3造と一致する。融点は148℃で ちる。Example 26 5-(2-chlorobenzoyl-2-hydroxy-benzene vinegar NMR spectra The molecular and elemental analysis data are consistent with the structure of the title compound. Melting point is 148℃ Chiru.
実施例27 5−ベンゾイル−2−メトキシ−ベンゼン酢a139tジメチルホルムアミド1 50dに溶解する。ナトリウム水素化吻xogt含むジメチルホルムアミド50 m(を加える。この溶液を水中で冷却しヨウ化メチル30ゴを少しずつ加える。Example 27 5-benzoyl-2-methoxy-benzene vinegar a139t dimethylformamide 1 Dissolves in 50d. Dimethylformamide 50 containing sodium hydride xogt Cool the solution in water and add 30 g of methyl iodide little by little.
約6時間後にこの溶液が室温まで温まる。最後のヨウ化メチルを更に16時間経 過した後に添加する。メタノールをその後加えこの溶液を氷水−塩は上に注ぐ。After about 6 hours the solution warms to room temperature. The last methyl iodide was added for another 16 hours. Add after cooling. Methanol is then added and the solution is poured over ice water-salts.
これをクロロホルムで抽出しその後得られた溶液を蒸発させる。残滓を50チ工 タノールIM水酸化ナトリウム溶液中で2時VJ沸騰させる。得られた溶液をり o 口*にムVC対して逗って先付させ、このクロロホルム相ヲ伐酸マグネシウ ムで脱水し蒸発させる。残滓を石油エーテルと攪拌し、上清をデカンテーション で除去し、残層部分を石油エーテル−ベンゼンから再結晶化させる。This is extracted with chloroform and the resulting solution is then evaporated. 50 pieces of residue Boil VJ in tanol IM sodium hydroxide solution for 2 hours. Pour the resulting solution o Put it in the mouth* and add it to the VC, and remove the magnesium chloride from this chloroform phase. Dehydrate and evaporate. Stir the residue with petroleum ether and decant the supernatant. The remaining layer is recrystallized from petroleum ether-benzene.
tb+ −ベン゛ ルー −ヒ′ロキシーαα−ジ ルーヘン立乙り区 本合成は実施例3(b)と同様に実施する。tb+ - Ben Lu - Hi'roxy αα - Ji Ruhen Tateotori Ward This synthesis is carried out in the same manner as in Example 3(b).
NMRスペクトラム及び元素分析のデータ表題化合物の構造と一致する。融点は 207℃である。The NMR spectrum and elemental analysis data are consistent with the structure of the title compound. The melting point is The temperature is 207°C.
実施例28 5−(3−(λ4−ジクロロフエニ/L/)−1−オキソ−2−プロペニル)− 2−とドロ牛シーベンゼン酢酸本合成は実施例xs(blと同様に実施する。Example 28 5-(3-(λ4-dichloropheny/L/)-1-oxo-2-propenyl)- The main synthesis of 2- and doro-shibenzene acetic acid is carried out in the same manner as in Example xs (bl).
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は232℃でおる。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point The temperature is 232℃.
実施例29 5− 3− 4− 1−メチル−エチル −フェニル −1−オキソ−2−プロ ペニル)−2−ヒドロキシ−ベンゼン酢酸本合成は実施例xs(blと同様に実 施する。Example 29 5-3-4-1-methyl-ethyl-phenyl-1-oxo-2-pro penyl)-2-hydroxy-benzeneacetic acid This synthesis was carried out similarly to Example xs (bl). give
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は228℃である。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 228°C.
実施例30 5−(3−(4−メトキンフェニル)−1−オキソ−2−プロペニル)−2−ヒ ドロキシ−ベンゼン酢酸本合成は実施例16fb)と同様に実施する。Example 30 5-(3-(4-methquinphenyl)-1-oxo-2-propenyl)-2-hyphenyl The main synthesis of droxy-benzeneacetic acid is carried out analogously to Example 16fb).
NMRスペクトラム及び元素分析のデータは表題化合物の44造と一致するっ融 点は247℃である。The NMR spectrum and elemental analysis data are consistent with the structure of the title compound. The point is 247°C.
実施例31 5−(3−(4−クロロフェニル)−1−オキソ−2−プロペニル)−2−ヒド ロキシ−ベンゼン酢酸本合成は実施例16th)と同様に実施する。Example 31 5-(3-(4-chlorophenyl)-1-oxo-2-propenyl)-2-hydro Roxy-benzeneacetic acid The main synthesis is carried out in the same manner as in Example 16th).
NMRスペクトラム及び元素分析のデータはM化合物の構造と一致する。融点( d244℃でるる。The NMR spectrum and elemental analysis data are consistent with the structure of the M compound. Melting point ( d Ruru at 244℃.
実施例32 5−(4−7セチルベンゾイル)−2−ヒドロキシ−ベンゼン酢飯 4−アセチル安息香酸109.塩化チオニル7ml及びジメチルホルムアミドl −を塩化メチレン1OO−に溶解させ5時間3書させる0この池喉をhaし、メ チル2−メトキシ−ベンゼンアセテ−)IL39を含む塩化メチレン50rxt と混合し、塩化アルミニウム40gを懸濁させた塩化メチレン100MtK滴下 し加える。この溶液を5時間沸騰させ、氷水上に注ぎクロロホルムで抽出する。Example 32 5-(4-7 cetylbenzoyl)-2-hydroxy-benzene vinegar rice 4-Acetylbenzoic acid 109. 7 ml thionyl chloride and 1 dimethylformamide Dissolve - in methylene chloride 100- and write for 3 hours for 5 hours. methylene chloride containing 2-methoxy-benzene acetate) IL39 50 rxt 100 MtK of methylene chloride mixed with aluminum chloride and suspended with 40 g of aluminum chloride was added dropwise. Add. The solution is boiled for 5 hours, poured onto ice water and extracted with chloroform.
このクロロホルム相を蒸発させ水酸化ナトリウム溶液中で加水分解する。これを 酸性化し酢酸エチルで抽出する。この酢酸エチル溶液を酋縮し、形成した結晶を 戸別する。この結晶を水−エタノール(3:1)及び水酸化ナトリウム中に溶解 させる。−を7に調節し、穏やかに加熱しながら活性炭処理する。この溶液を酸 性化し冷却する。生成物を戸別し結晶をもう一度同じ方法で単離する。The chloroform phase is evaporated and hydrolyzed in sodium hydroxide solution. this Acidify and extract with ethyl acetate. This ethyl acetate solution is condensed and the formed crystals are Go door to door. The crystals were dissolved in water-ethanol (3:1) and sodium hydroxide. let - Adjust to 7 and treat with activated carbon while heating gently. Add this solution to the acid Sexualize and cool. The product is separated and the crystals are isolated again in the same manner.
NMRスペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は235cである。NMR spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 235c.
実施例33 2−ヒドロキシ−5−(2−(4−カルボキシフェニル)−1M水酸化ナトリウ ム75−に溶解する。506gの水素化臭素ナトリウムを少しずつ加える。この 溶液を25時間沸騰させる。Example 33 2-hydroxy-5-(2-(4-carboxyphenyl)-1M sodium hydroxide 75-. Add 506 g of sodium bromine hydride in portions. this Boil the solution for 25 hours.
1M塩酸を15ONt;IJIIIえる。生成物を酢酸エチルで抽出する。Add 15 ONt of 1M hydrochloric acid. The product is extracted with ethyl acetate.
有機相を乾燥させ蒸発乾燥させる。残滓を酢酸7s*に溶解し&硫ば16−を加 える。生成物はこO浴液力)ら直捩耐晶化する。The organic phase is dried and evaporated to dryness. Dissolve the residue in acetic acid 7s* and add sulfur 16- I can do it. The product is crystallized directly from the O bath.
これを*V化ナナトリウム氾解し次いでギ酸で酸性化して、こ致する。融点は2 60℃よシ高い。This is dissolved in sodium V chloride and then acidified with formic acid. The melting point is 2 It's as high as 60 degrees Celsius.
実施例34 2−ヒ)”0?シー5−(2−フェニル−1−エチニル)−ベンゼン酢酸 2−ヒドロキー/−5−(2−フェニルアセチル)−ベンゼン酢酸α68り、水 素化臭素ナトリウムα95g、テトラヒドロ7ラン2〇−及び1M水酸化ナトリ ウム20mを1時間還流する。この溶液を100−のエーテルと伴に振って混合 する。水相を声3まで酸性化しエーテル50−で3回抽出する。このエーテル相 を合わせて脱水し蒸発乾燥する。Example 34 2-H)"0?C 5-(2-phenyl-1-ethynyl)-benzeneacetic acid 2-hydroxy/-5-(2-phenylacetyl)-benzeneacetic acid α68, water Sodium bromine α95g, tetrahydro7ran 20- and 1M sodium hydroxide Reflux 20 m of aluminum for 1 hour. Shake and mix this solution with 100- ether. do. The aqueous phase is acidified to 3°C and extracted 3 times with 50°C of ether. This etheric phase Combine, dehydrate and evaporate to dryness.
残滓を酢酸16−及び濃硫酸4dに溶解する。この溶液を15分闇沸騰させ、水 上に注ぎエーテルで抽出し、その後このエーテル相を蒸発させる。The residue is dissolved in 16 d of acetic acid and 4 d of concentrated sulfuric acid. Boil this solution in the dark for 15 minutes, then add water Pour on top and extract with ether, then evaporate this ether phase.
この残滓をIM水酸化ナトリクムに溶解する。塩酸を加えると生成物が結晶化し てくる。This residue is dissolved in IM sodium hydroxide. When hydrochloric acid is added, the product crystallizes. It's coming.
N M Rスペクトラム及び元素分析のデータは表題化合物の薄造と一致する6 融点は202℃である。NMR spectrum and elemental analysis data are consistent with the thin structure of the title compound6 The melting point is 202°C.
実施例35 5− 2−メチル−1−オキソ−3−フェニル−2−グロペニル −2−ヒドロ キシ−ベンゼン酢酸 メチル5−プロパノイル−2−ヒドロキシ−ベンゼン酢酸119、ベンズアルデ ヒド1α6g、エタノール150 mt及ヒ塩化水素で飽和させたエーテル50 ゴを5日間還流させる。この溶液を水上に注ぎ酢酸エチルで抽出する。この酢酸 エチルを蒸発させ残滓を水酸化す) IJウム溶液中で加水分解する。−を7に 調節しこの溶液を酢酸エチルで洗浄する。水相を塩酸で酸性化し酢酸エチルで抽 出する。この酢酸エチルを蒸発させ、残滓をジクロロエタンで浸出させ2−ブタ ノン/L2−ジクロロエタンから再結晶化させる。Example 35 5-2-methyl-1-oxo-3-phenyl-2-gropenyl-2-hydro xy-benzeneacetic acid Methyl 5-propanoyl-2-hydroxy-benzeneacetic acid 119, benzalde 6 g of hydride 1α, 150 mt of ethanol and 50 mt of ether saturated with hydrogen arsenide chloride Reflux the mixture for 5 days. The solution is poured onto water and extracted with ethyl acetate. This acetic acid Evaporate the ethyl and hydroxylate the residue) Hydrolyze in IJum solution. - to 7 Adjust and wash this solution with ethyl acetate. The aqueous phase was acidified with hydrochloric acid and extracted with ethyl acetate. put out The ethyl acetate was evaporated and the residue was leached with dichloroethane and 2-butane Recrystallize from non/L2-dichloroethane.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は192℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 192°C.
実施例36 本合成は実施例16(b)と同様に実兄する。Example 36 This synthesis is similar to Example 16(b).
NMRMペクトラム及び元素分析のデータは表題化合物の4遣と一致する。融点 は235℃である。NMRM spectrum and elemental analysis data are consistent with the title compound. melting point is 235°C.
冥 鳳 例 37 5−(3−(4−シアノフェニル)−1−オキソ−2−プロペニルジ−2−ヒド ロキシ−ベンゼン酢酸本合成は実力例x6(b)と同様に契施する。Meiho Example 37 5-(3-(4-cyanophenyl)-1-oxo-2-propenyl di-2-hydride The main synthesis of roxy-benzene acetic acid was carried out in the same manner as in Example x6(b).
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は249℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 249°C.
実施例38 5−(”3−(4−)リフルオロメチルフェニル)−1−オキソ−2本合成Fi 笑施例16(blと同様に実施する。Example 38 5-("3-(4-)lifluoromethylphenyl)-1-oxo-2 synthesis Fi Example 16 (conducted in the same manner as in BL).
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は260℃よシ高い。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is as high as 260℃.
実施例39 本合成は実施例1s(b>と同様に実施する。Example 39 This synthesis is carried out in the same manner as in Example 1s(b>).
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は210℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 210°C.
実 施 例 40 5−(3−(λ4−ジメトキシフェニル)−1−オキソ−2−プロペニルツー2 −ヒドロキシ−ペン’r! 7 酢d本合成は実施例16th)と同様に実施す る。Implementation example 40 5-(3-(λ4-dimethoxyphenyl)-1-oxo-2-propenyl2 -Hydroxy-Pen’r! 7 Vinegar d Main synthesis was carried out in the same manner as in Example 16th). Ru.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する@融点 は225℃であるっ実施例41 本合成は実施例10と同様に実施するうNMRMペクトラム及び元素分析のデー タは表題化合物の構造と一致する。融点は149℃である。NMRM spectrum and elemental analysis data are consistent with the structure of the title compound @ melting point is 225°C Example 41 This synthesis was carried out in the same manner as in Example 10. The NMRM spectrum and elemental analysis data were ta is consistent with the structure of the title compound. The melting point is 149°C.
実施例42 5−4−二トロベンソイル −2−ヒドロキシ−ベンセン酸 本合成は実施例10と同様に実施する。Example 42 5-4-nitrobenzoyl-2-hydroxy-benzoic acid This synthesis is carried out in the same manner as in Example 10.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は213℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point is 213°C.
実施例43 5− 4−メチルベンゾイル −2−ヒドロキシ−ベンゼン酢不合瓜は笑只例1 0と同様に来光する。Example 43 5-4-Methylbenzoyl-2-hydroxy-benzene The light will come in the same way as 0.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 IF 218℃である。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point IF is 218°C.
実施例44 本合成は実施例10と同様に実施する。生成物をクロロホルムに溶解し水と一緒 に混合する。同時に水酸化ナトリウムを加え−を7.2に合せる。相を分離しそ の水相を凍結乾燥する。Example 44 This synthesis is carried out in the same manner as in Example 10. Dissolve the product in chloroform and add water Mix with At the same time, add sodium hydroxide and adjust to 7.2. Separate the phases Lyophilize the aqueous phase.
NMRMペクトラム及び元素分析のデータは表題化合物の構造と一致する。融点 は約170℃でちる2実施例45 本合成は実施例10と同様に実施する。NMRM spectra and elemental analysis data are consistent with the structure of the title compound. melting point Chills at about 170°C 2 Example 45 This synthesis is carried out in the same manner as in Example 10.
NM几ススペクトラムび元素分析のデータは表題化合物の構造と一致する。融点 は186℃である。The NM concentration spectrum and elemental analysis data are consistent with the structure of the title compound. melting point is 186°C.
実施例46 5−ベンゾイル−2−ヒドロキシ−6−メチルーペンゼ/酢酸本合成は実施例1 0と同様に実施する。Example 46 5-benzoyl-2-hydroxy-6-methylpenze/acetic acid Main synthesis Example 1 Execute in the same manner as 0.
N)JRスペクトラム及び元素分析のデータは表題化置物の構造と一致する。融 点は212℃である。N) JR spectrum and elemental analysis data are consistent with the structure of the titled ornament. Melt The point is 212°C.
冥施例47 15−ヒドロキシ−プロスタグランジンデヒドロゲナーゼの阻害15−ヒドロキ シ−グロスタグランジンデヒドロゲナーゼ(PGDH)の阻害剤としての前記化 合物の効果をin vitroの測定で示す。ホルト()(oult)及びモア (Moore)の記Vt、<ブリティシュ・ジャーナル・オン−77−マコロジ ー: Br1tish Journal ofPharmacolosy 61 巻、 (1977)、a 1s頁)によって調製した細胞を除去したヒト胎盤( PGDH含有)と放射性グロスタグランジンF、(PGF、)を−緒にインキュ ベートする。適当なインキュベーション時間後にブロスタグ2ンジンを抽出しク ロマトグラフィによって分岐する。そして変化していないP G F*の量1代 謝孟物の量と比較する。加える阻害剤の量を様々に変え、阻害剤を加えないで行 った対照実験に較べて、分解の50チ阻°害が達成されるそれらの化合物の濃度 (ICIII)を測定することによって阻害効果を評価する。lOμM又はそれ 以下の濃度でPGDH050%を阻害するものを優れた( Very good )il害剤と考える。10及び100μMの間の&度でPGDHの50チを阻害 するものを良好な(good )阻害剤と考える。化合物が良好とは言えない( 1ess good )ものとして類別される猶合には1.これは5il際の投 与に於いてri例えば低毒性又F′i荷に逸切な薬物動感学的特性のような他の 重要な特性によって相殺さnることかしばしば見受けられる。Meiji Example 47 Inhibition of 15-hydroxy-prostaglandin dehydrogenase 15-hydroxy-prostaglandin dehydrogenase As an inhibitor of sea-glostaglandin dehydrogenase (PGDH) The effect of the compound is shown by in vitro measurements. holt (oult) and more (Moore) Vt, <British Journal on-77-Makologie -: Br1tish Journal of Pharmacology 61 (1977), p. a1s) from which cells had been removed (Human placenta) PGDH-containing) and radioactive grosstaglandin F, (PGF) were incubated together. Bate. After an appropriate incubation time, extract the broth-tagged 2-ginsin. Branched by chromatography. And the amount of P G F * that has not changed is 1 generation Compare it with the amount of praise. Varying the amount of inhibitor added and performing experiments without adding inhibitor. Concentrations of those compounds at which 50% inhibition of degradation is achieved compared to control experiments The inhibitory effect is evaluated by measuring (ICIII). lOμM or less A substance that inhibits PGDH050% at the following concentrations is very good. ) considered as a harmful agent. Inhibits 50% of PGDH at degrees between 10 and 100 μM A good inhibitor is one that does so. The compound cannot be said to be good ( 1ess good). This is a throw at 5il. In certain cases, ri may have other properties such as low toxicity or pharmacokinetic properties distinct from F'i loading. It is often found that the characteristics are offset by important characteristics.
不発明による数多くの化合物のICIII値を以下の我に記載する◎比較の為、 欧州特許公開第21229号明−薔に記載の公知PGDH有効阻害剤、5−フェ ニルアゾ−2−ヒドロキシベンゼン酢酸のIC1゜値も我に記載する。新規な化 合物i−j PGDH阻害効果があるにもかかわらずその毒性は比較的低いもの である。毒性に関して倹約した本発明の数多くの化合物に於いて、マウスの腹腔 内投与による測定では急性毒性″j;kll′1300ないし728ダ/に9で ある。The ICIII values of a number of uninvented compounds are listed below.◎For comparison, The known PGDH effective inhibitor described in European Patent Publication No. 21229 Mei-Bara, 5-phere The IC1° value for nilazo-2-hydroxybenzeneacetic acid is also listed. novelization Compound i-j: Despite its PGDH inhibitory effect, its toxicity is relatively low It is. In a number of the compounds of the invention that are sparing with respect to toxicity, the intraperitoneal When measured by internal administration, the acute toxicity was 9 in 1300 to 728 Da/. be.
国際1Aを部央 bw−m、、= a□+−−PCT/SEI]5100020mAMkPcT/ SEa5100020International 1A section center bw-m,,= a□+--PCT/SEI]5100020mAMkPcT/ SEa5100020
Claims (11)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8400239-3 | 1984-01-19 | ||
| SE8400239A SE8400239D0 (en) | 1984-01-19 | 1984-01-19 | NEW ARYLETIC ACID DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS61500915A true JPS61500915A (en) | 1986-05-08 |
Family
ID=20354351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60500499A Pending JPS61500915A (en) | 1984-01-19 | 1985-01-18 | New aryl acetic acid derivatives |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4695648A (en) |
| EP (2) | EP0150166B1 (en) |
| JP (1) | JPS61500915A (en) |
| AT (1) | ATE35809T1 (en) |
| AU (1) | AU574129B2 (en) |
| CA (1) | CA1276938C (en) |
| DE (1) | DE3563847D1 (en) |
| DK (1) | DK424585A (en) |
| FI (1) | FI853586A7 (en) |
| NO (1) | NO853573L (en) |
| SE (1) | SE8400239D0 (en) |
| WO (1) | WO1985003287A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004101483A1 (en) * | 2003-05-14 | 2006-07-13 | 独立行政法人理化学研究所 | Novel trisubstituted benzene derivative, process for producing the same, and pharmaceutical composition containing the same |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177259A (en) * | 1986-04-11 | 1993-01-05 | Warner-Lambert Company | Diarylalkanoids having activity as lipoxygenase inhibitors |
| CA1320490C (en) * | 1987-01-12 | 1993-07-20 | Darrel M. Gapinski | Anti-inflammatory agents |
| US4992576A (en) * | 1987-01-12 | 1991-02-12 | Eli Lilly And Company | Intermediates for leukotriene antagonists |
| US5171882A (en) * | 1987-01-12 | 1992-12-15 | Eli Lilly And Company | Leukotriene antagonists |
| US5235064A (en) * | 1987-01-12 | 1993-08-10 | Eli Lilly And Company | Leukotriene antagonists |
| IT1222448B (en) * | 1987-08-06 | 1990-09-05 | Balschim S P A | PROCEDURE FOR PREPARING KETOPROFEN |
| US5196564A (en) * | 1988-05-20 | 1993-03-23 | Takeda Chemical Industries, Ltd. | Physiologically active substance TAN-931, its derivatives, their production and use |
| US4996230A (en) * | 1990-02-16 | 1991-02-26 | Eli Lilly And Company | Leukotriene antagonists |
| DE4028866A1 (en) * | 1990-09-07 | 1992-03-12 | Schering Ag | NEW LEUKOTRIEN-B (ARROW DOWN) 4 (ARROW DOWN) ANTAGONISTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
| SK280617B6 (en) * | 1992-01-16 | 2000-05-16 | Hoechst Aktiengesellschaft | Arylcycloalkyl derivatives, method of their preparation, pharmaceutical compositions them containing, and their use |
| US5827805A (en) * | 1996-02-29 | 1998-10-27 | The Lubrizol Corporation | Condensates of alkyl phenols and glyoxal and products derived therefrom |
| KR100702686B1 (en) * | 1998-11-05 | 2007-04-04 | 토야마 케미칼 컴퍼니 리미티드 | New compounds and their medical uses |
| US6939835B2 (en) * | 1999-03-26 | 2005-09-06 | Firmenich Sa | Cyclic compounds and their use as precursors of fragrant alcohols |
| ES2163986B1 (en) * | 1999-07-13 | 2003-02-16 | Menarini Lab | ACIDOS-ALFA-ARILPROPIONICOS AND ARILACETICOS AS INHIBITORS OF CYCLLOXYGENASA-II. |
| CN101675927A (en) | 2002-06-07 | 2010-03-24 | 科蒂科股份有限公司 | therapeutic molecules and methods-1 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828093A (en) * | 1967-07-31 | 1974-08-06 | Allen & Hanburys Ltd | Benzoylphenylacetic acids and related compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH537354A (en) * | 1968-08-15 | 1973-05-31 | Lilly Co Eli | Anti-inflammatory substd-phenylalkanoic acids and |
| GB1307284A (en) * | 1970-03-16 | 1973-02-14 | Boots Co Ltd | 2-substituted phenyl propionic acids |
| OA04219A (en) * | 1971-12-03 | 1979-12-31 | Rhone Poulenc Sa | Novel process for the preparation of (3-benzol-phenyl) -2 propionic acid and the like. |
| JPS5111748A (en) * | 1974-07-16 | 1976-01-30 | Taisho Pharmaceutical Co Ltd | Suchirubenjudotaino seizoho |
| CS175831B1 (en) * | 1974-12-17 | 1977-05-31 | ||
| CH577461A5 (en) * | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
| DE2702911A1 (en) * | 1977-01-21 | 1978-07-27 | Schering Ag | 4-Cycloalkyl- or 4-cyclo:alkanoyl-phenyl-acetic acid derivs. - used as systemic antiinflammatory agents |
| US4161538A (en) * | 1977-04-05 | 1979-07-17 | Sankyo Company Limited | Substituted phenylacetic acid derivatives and process for the preparation thereof |
| DE2826437A1 (en) * | 1978-06-14 | 1980-01-03 | Schering Ag | 4-Cycloalkyl:methyl-phenyl-acetic acid derivs. - useful as antiinflammatories e.g. for treating arthritis |
| YU39566B (en) * | 1978-04-07 | 1984-12-31 | Lek Tovarna Farmacevtskih | Process of preparing 2-(3-benzoyl-phenyl)-propionic acid |
| DE2861078D1 (en) * | 1978-07-21 | 1981-12-03 | Schering Ag | Indan-1-carboxylic acid derivatives,process for their preparation and pharmaceutical preparations containing these compounds |
| JPS5731640A (en) * | 1980-07-30 | 1982-02-20 | Toyama Chem Co Ltd | Dicarboxylic acid and its preparation |
| JPS5764639A (en) * | 1980-10-04 | 1982-04-19 | Nippon Zoki Pharmaceut Co Ltd | Novel stilbene derivative, its preparation, and medical composition containing the same as active ingredent |
| FR2492815A1 (en) * | 1980-10-23 | 1982-04-30 | Sori Soc Rech Ind | NEW CINNAMOYL-CINNAMIC ACID DERIVATIVE, PREPARATION METHOD AND THERAPEUTIC APPLICATION THEREOF |
-
1984
- 1984-01-19 SE SE8400239A patent/SE8400239D0/en unknown
-
1985
- 1985-01-18 FI FI853586A patent/FI853586A7/en not_active Application Discontinuation
- 1985-01-18 AT AT85850020T patent/ATE35809T1/en not_active IP Right Cessation
- 1985-01-18 DE DE8585850020T patent/DE3563847D1/en not_active Expired
- 1985-01-18 US US06/775,058 patent/US4695648A/en not_active Expired - Fee Related
- 1985-01-18 EP EP85850020A patent/EP0150166B1/en not_active Expired
- 1985-01-18 EP EP85900799A patent/EP0168467A1/en not_active Withdrawn
- 1985-01-18 CA CA000472414A patent/CA1276938C/en not_active Expired - Fee Related
- 1985-01-18 WO PCT/SE1985/000020 patent/WO1985003287A1/en not_active Ceased
- 1985-01-18 AU AU38830/85A patent/AU574129B2/en not_active Ceased
- 1985-01-18 JP JP60500499A patent/JPS61500915A/en active Pending
- 1985-09-12 NO NO853573A patent/NO853573L/en unknown
- 1985-09-18 DK DK424585A patent/DK424585A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828093A (en) * | 1967-07-31 | 1974-08-06 | Allen & Hanburys Ltd | Benzoylphenylacetic acids and related compounds |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004101483A1 (en) * | 2003-05-14 | 2006-07-13 | 独立行政法人理化学研究所 | Novel trisubstituted benzene derivative, process for producing the same, and pharmaceutical composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1276938C (en) | 1990-11-27 |
| EP0150166A1 (en) | 1985-07-31 |
| EP0168467A1 (en) | 1986-01-22 |
| US4695648A (en) | 1987-09-22 |
| EP0150166B1 (en) | 1988-07-20 |
| AU574129B2 (en) | 1988-06-30 |
| FI853586L (en) | 1985-09-18 |
| AU3883085A (en) | 1985-08-09 |
| DK424585D0 (en) | 1985-09-18 |
| SE8400239D0 (en) | 1984-01-19 |
| WO1985003287A1 (en) | 1985-08-01 |
| FI853586A0 (en) | 1985-09-18 |
| DK424585A (en) | 1985-09-18 |
| NO853573L (en) | 1985-09-12 |
| FI853586A7 (en) | 1985-09-18 |
| ATE35809T1 (en) | 1988-08-15 |
| DE3563847D1 (en) | 1988-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61500915A (en) | New aryl acetic acid derivatives | |
| TW414790B (en) | A restricted 9-cis-retinoid compound, the preparation process and the pharmaceutical composition for treating atherosderosis and leukemias thereof | |
| JP4051712B2 (en) | Novel melatonin-acting β-carboline derivatives and analogs containing naphthalene structure, their production method and pharmaceutical use | |
| JPH0231079B2 (en) | ||
| NO760003L (en) | ||
| JPH0755921B2 (en) | Amides | |
| EP0114014B1 (en) | Thieno(2,3-b) pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JPH06509558A (en) | Novel aromatic polycyclic compounds and their use in human or veterinary medicine and cosmetics | |
| JPS5915889B2 (en) | Method for producing ethynylbenzene compound | |
| US5288750A (en) | Substituted β-diketones | |
| US4694018A (en) | Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives | |
| JPH0717589B2 (en) | Novel 1,3-dicarbonyl compound and composition thereof | |
| FR2467840A1 (en) | BENZOYL-3 NITRO-2 PHENYLACETIC ACIDS AND METAL SALTS, AMIDES AND CORRESPONDING ESTERS USEFUL IN PARTICULAR AS ANTI-INFLAMMATORY DRUGS THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMATES CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | |
| US3385887A (en) | 4-isobutylphenylacetic acid | |
| KR20080015788A (en) | Benzoic acid derivatives which are modifiers or agonists of GlyR | |
| EP0463944A1 (en) | Acylbenzoxazolinones, process for their preparation and pharmaceutical compositions containing them | |
| JPH0859458A (en) | Hyperlipidemia therapeutic agent containing indane derivative | |
| JPS6033373B2 (en) | 1-naphthyl acetic acid derivatives, their production methods, and drugs containing 1-naphthyl acetic acid derivatives | |
| JPS6140280A (en) | 5,6_dihydro_4h_cyclopenta(b)thiophene_6_ carboxylic acid, manufacture and medicinal composition | |
| JPS6270351A (en) | Substituted di-t-butylphenols | |
| JPH0755939B2 (en) | Novel benzothiazolinone derivative | |
| US2436270A (en) | Polyiodo diaryl aliphatic acids and process for their manufacture | |
| CA1088554A (en) | Preparation of 5-substituted indane-2 carboxylic acid and derivatives | |
| JPH0422912B2 (en) | ||
| WO2019232665A1 (en) | Thiolized indolizine compound having anticancer activity and derivative thereof |